
==== Front
Int J Mol Sci
Int J Mol Sci
ijms
International Journal of Molecular Sciences
1422-0067
MDPI

10.3390/ijms23073609
ijms-23-03609
Review
Mechanistic Insights into Selective Autophagy Subtypes in Alzheimer’s Disease
Guan Xinjie 12
Iyaswamy Ashok 12
Sreenivasmurthy Sravan Gopalkrishnashetty 12
Su Chengfu 12
https://orcid.org/0000-0002-0642-8919
Zhu Zhou 12
Liu Jia 12
Kan Yuxuan 1
Cheung King-Ho 12
https://orcid.org/0000-0002-1147-125X
Lu Jiahong 3
Tan Jieqiong 4*
https://orcid.org/0000-0002-7113-2700
Li Min 12*
Rostagno Agueda A. Academic Editor
Baranowska-Bik Agnieszka Academic Editor
Orzechowski Arkadiusz Academic Editor
1 Mr. & Mrs. Ko Chi-Ming Centre for Parkinson’s Disease Research, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China; 21481555@life.hkbu.edu.hk (X.G.); iashok@hkbu.edu.hk (A.I.); sravangs@hkbu.edu.hk (S.G.S.); 20481403@life.hkbu.edu.hk (C.S.); zhuzhou1@hkbu.edu.hk (Z.Z.); 20482248@life.hkbu.edu.hk (J.L.); yuxuan@hkbu.edu.hk (Y.K.); kingho@hkbu.edu.hk (K.-H.C.)
2 Institute for Research and Continuing Education, Hong Kong Baptist University, Shenzhen 518057, China
3 State Key Lab of Quality Research in Chinese Medicine, University of Macau, Macao, China; jiahonglu@um.edu.mo
4 Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410000, China
* Correspondence: tanjieqiong@sklmg.edu.cn (J.T.); limin@hkbu.edu.hk (M.L.)
25 3 2022
4 2022
23 7 360927 2 2022
23 3 2022
© 2022 by the authors.
2022
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Eukaryotic cells possess a plethora of regulatory mechanisms to maintain homeostasis and ensure proper biochemical functionality. Autophagy, a central, conserved self-consuming process of the cell, ensures the timely degradation of damaged cellular components. Several studies have demonstrated the important roles of autophagy activation in mitigating neurodegenerative diseases, especially Alzheimer’s disease (AD). However, surprisingly, activation of macroautophagy has not shown clinical efficacy. Hence, alternative strategies are urgently needed for AD therapy. In recent years, selective autophagy has been reported to be involved in AD pathology, and different subtypes have been identified, such as aggrephagy, mitophagy, reticulophagy, lipophagy, pexophagy, nucleophagy, lysophagy and ribophagy. By clarifying the underlying mechanisms governing these various subtypes, we may come to understand how to control autophagy to treat AD. In this review, we summarize the latest findings concerning the role of selective autophagy in the pathogenesis of AD. The evidence overwhelmingly suggests that selective autophagy is an active mechanism in AD pathology, and that regulating selective autophagy would be an effective strategy for controlling this pathogenesis.

Alzheimer’s disease
selective autophagy
aggrephagy
mitophagy
reticulophagy
lipophagy
pexophagy
nucleophagy
ribophagy
lysophagy
==== Body
pmc1. Introduction

Alzheimer’s disease (AD) is the most prevalent progressive neurologic disorder affecting aged people worldwide. Clinically, the primary manifestation of AD is memory impairment, followed by deficits in cognitive and adaptive functioning as the disease progresses [1,2,3]. On the basis of several factors, AD can be broadly categorized as familial and sporadic AD. Familial AD, also known as early onset AD, is often associated with genetic mutations, such as mutations in amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2). Sporadic AD is often caused by environmental and complex genetic factors such as the presence of the epsilon4 allele in apolipoprotein E (APOE) [4]. Pathologically, AD is characterized by the accumulation of tau-enriched neurofibrillary tangles (NFTs) and β-amyloid (Aβ) toxic aggregates in the hippocampus and cerebral cortex of the brain [5], which are the major pathological markers of AD [6,7]. According to previous studies, an accumulation of NFTs leads to synaptic dysfunction, which further causes a decline in memory and cognitive functions. Moreover, Aβ oligomers disrupt calcium homeostasis by binding to receptors, activating calcineurin and caspases [8]. In AD patients, a large number of aggregated toxic proteins interfere with the normal function of autophagy, further aggravating the pathogenesis of AD. Increasing evidence has suggested that autophagy, through which damaged organelles and misfolded proteins are degraded and then recycled to maintain proteostasis, plays a major role in AD. The mammalian nervous system, especially the neurons, is largely dependent on autophagy to clear large amounts of insoluble protein aggregates to maintain protein homeostasis [9]. Initially, autophagosomes and autolysosomes were found to accumulate in AD brains [10]. Early studies demonstrated that Beclin-1, a core subunit of the vacuolar protein-sorting 34 (VPS34) complex, decreases as AD progresses [11,12,13]. Interestingly, phosphatidylinositol 3-phosphate (PI3P) production, mediated by the VPS34 complex, is also downregulated in AD patients’ brains [14]. Autophagy is a protective mechanism in response to stress in the early stages of AD, but autophagic flux is reduced in the late stages of AD [15]. In our previous studies, we found that many Chinese herbs, formulas and compounds have neuroprotective effects and can promote the clearance of Aβ and tau proteins through enhancing autophagy and rescuing memory and cognitive impairment in AD mouse models [16,17,18,19,20]. Mounting evidence is leading to the conclusion that dysfunctional autophagy is strongly linked to AD pathogenesis.

In neurodegenerative diseases, especially AD, activating autophagy can promote cell survival by removing damaged organelles and protein deposits. Autophagy thereby provides additional energy, and dictates the fate and function of various cellular organelles [21]. According to the different pathways by which the cargo can be degraded in lysosomes, autophagy can be divided into three types: macroautophagy, microautophagy, and molecular chaperone-mediated autophagy (CMA). In macroautophagy, the double-membrane autophagosome wraps the cargo to be degraded, fuses with the lysosome, and degrades in the lysosome; this is the most common form of autophagy [22]. In conditions of nutrient imbalance, autophagy is generally a nonselective cellular degradation process. However, damaged and excess cellular organelles such as mitochondria, ER, lysosomes, and protein aggregates can also be degraded in a highly selective manner through selective autophagy [23]. For this type of autophagy, some autophagy-related proteins are required to ensure specific recognition and degradation of the cargo [21]. For example, the autophagy-related protein 8 (Atg8) family proteins on autophagosomes can target specific proteins for degradation. Microautophagy refers to the transport of cargo into lysosomes through lysosomal membrane invagination for degradation [24]. CMA refers to the process in which the cargo to be degraded binds to molecular chaperones and directly targets the lysosomes for degradation [25]. Heat shock cognate protein 70 (Hsc70) transports the target protein to the lysosomal receptor for degradation [26]. Ubiquitination is a marker of targeted protein degradation [27]. A variety of selective autophagy processes have been discovered and named according to their cellular targets, such as mitophagy (mitochondria), reticulophagy (the ER), lipophagy (lipid droplets), pexophagy (the peroxisome), nucleophagy (the nucleus), ribophagy (the ribosome), and lysophagy (the lysosome). All of the abovementioned selective autophagy subtypes are essential for maintaining proper cellular homeostasis [28].

Selective autophagy dysfunction is correlated with AD pathogenesis [29,30]. Aggrephagy and mitophagy dysfunction have been shown in the clearance of aggregated proteins and damage mitochondrial in AD patients [31]. There is some research on the link between AD and reticulophagy, which indicates that reticulon 3 (RTN3) aggregation, interferes with reticulophagy, and increases Aβ levels in elderly people [32]. Moreover, the presence of large amounts of lipid droplets (LDs), such as cholesteryl esters in the neurons, reduces the activity of the proteasomes, thereby promoting the accumulation of p-tau protein, further contributing to the pathogenesis of AD [33]. Therefore, clarifying the mechanism of selective autophagy in the pathogenesis of AD may lead us to a strategy for the prevention and treatment of AD. In this review, we summarize the current knowledge on the mechanisms of the various subtypes of selective autophagy in AD pathogenesis.

2. Aggrephagy

Generally, toxic aggregates cause neuronal membrane permeability damage, calcium homeostasis dysfunction, inflammation, neurotoxicity, and physiological abnormalities [34,35,36]. Aggrephagy is a subtype of selective autophagy that clears toxic protein aggregates [37]; in that sense, it reduces AD pathology. Aggregates are moved into double-membrane autophagosomes, where they are degraded in the acidic lysosomal lumen. The receptor SQSTM1-p62 (p62), the neighbor of BRCA1 gene 1 (NBR1), and the large junction protein ALFY are important in aggrephagy. A deficiency of ALFY or p62 is associated with neurodegeneration [38,39]. Autophagic receptors such as NBR1 and p62 directly bind to Atg8 homologs on autophagosomes for the degradation of protein aggregates [40,41,42,43,44]. Furthermore, CMA and the ubiquitin–proteasome system (UPS) prevent increases in soluble and insoluble protein aggregation [45]. Heat shock proteins such as Hsp40, Hsp60, Hsp70, and Hsp90 bind to the misfolded protein, neutralize hydrophobic areas exposed by the misfolded proteins, and prevent aggregation [46]. In CMA, Hsc70 binds to the KFERQ motif of the misfolded protein and is delivered to lysosomes for degradation by LAMP2a [47]. Ubiquitination of aggregates is critical for degradation in UPS and classical autophagy systems [48]. Existing studies have shown that ubiquitin interacts with seven lysine residues (K6, K11, K27, K29, K33, K48, and K63) [49]. These seven lysine residues bind with aggregates covalently, forming polyubiquitin chains for degradation [50].

AD is a proteinopathy, with the aggregation of Aβ and P-tau protein in the brain leading to memory deficits and neurodegeneration. The elevated Aβ-42 monomers gradually assemble into aggregates within the perinuclear space [51]. Normally, ubiquitin protein binds with Aβ for UPS degradation [52]. However, these polyubiquitin chains are unstable when bound with Aβ. Therefore, they cannot fold properly, and Aβ folding dysfunction changes their physicochemical properties and promotes the formation of Aβ fibers and plaques. Overall, due to polyubiquitination, Aβ is unfolded, causing the unfolded Aβ aggregates to develop into insoluble Aβ fibers. During aggregation, some polyubiquitin Aβ peptides are degraded normally by autophagy. Other polyubiquitin Aβ fibers and plaques bind to the UBA domains of p62 and NBR1 selectively, initiating degradation by aggrephagy [53].

Clinically, in the brains of AD patients, an enormous amount of extracellular Aβ and intracellular neurofibrillary tangles can be found [54]. NFTs are formed by abnormal aggregation and hyperphosphorylation of tau into paired helical filaments (PHFs) [55]. P-tau is transported to the nucleus to form aggregates for lysosomal degradation [56]. When proteasomal aggregation degradation is inhibited, Hsc70 interacts with CHIP to regulate tau ubiquitination [57]. Ubiquitinated P-tau is recruited by the aggregation receptor p62 [56,58]. HDAC6 binds with p62 and enhances retrograde transport of the P-tau and p62 complex to form tau aggregates [59]. Furthermore, HDAC6 has been reported to respond to the protease imbalance induced by proteasome inhibition and recombine with the cytoskeletal actin network to induce the formation of tau aggregates [60]. It has been reported that the ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) enzyme also affects the formation of tau protein aggregates. UCHL1 is a deubiquitinating enzyme that is abundantly expressed in the brain [61]. UCHL1 inhibition leads to hyperphosphorylation of tau protein and tau microtubule-stabilizing dysfunction [62]. In addition, UCHL1 can regulate the activity of HDAC6 and affect the formation of tau protein aggregates. Inhibition of UCHL1 impairs the interaction between P-tau and HDAC6, inhibiting the formation of tau aggregates [63]. Undoubtedly, specific aggregate degradation is required to prevent AD progression. Figure 1 illustrates the toxic protein aggregates degraded by the mechanism of aggrephagy in AD.

3. Mitophagy

Mitochondria are critical for synaptic transmission, synaptic plasticity, calcium homeostasis, and neuronal survival [64,65]. Damaged mitochondria are degraded through mitophagy [66,67]. Impaired mitophagy is associated with a variety of neurodegenerative diseases, including AD [28]. Mitochondrial dysfunction appears with age, but it is exacerbated in AD [68,69,70,71]. Mitochondria are key targets of autophagy in AD patient brains [72,73]. In AD models, mitochondrial swelling, abnormal morphology, and the accumulation of large numbers of damaged mitochondria have been found [74,75,76]. For example, when the mitochondria are damaged, the membrane potential decreases, which stabilizes PINK1 to the outer membrane. PINK1 phosphorylates and recruits the E3 ubiquitin ligase Parkin to the mitochondria, and mediates the ubiquitination of mitochondrial outer membrane proteins to mark impaired mitochondria for degradation through mitophagy [77]. Increased PINK1, Parkin, and mitochondrial protein ubiquitination were detected in an AD mouse model, suggesting that the mitophagy process is activated but stalled [78]. This may be due to an insufficient capacity to remove many damaged mitochondria, thereby resulting in the accumulation of impaired mitochondria and disturbance of mitochondrial homeostasis. In addition, corresponding to the age-related increase in AD incidence, mitochondrial dysfunction and mitophagy also increase with age [79].

Impairment of the mitochondria occurs in the early stages of AD, and this impairment can even appear before Aβ and NTFs are formed [80,81,82,83]. Decreases in oxidative phosphorylation, an increase in ROS production, and downregulation of the tricarboxylic acid cycle (TCA) have been reported [84,85]. Studies have found that the energy metabolism in AD patients’ brains is lower than normal, which may be due to mitochondrial dysfunction [86]. PGC-1-alpha, a major regulator of mitochondrial biogenesis, is decreased in AD patients’ brains, indicating mitochondrial dysfunction [87,88]. In addition, the accumulation of damaged mitochondria has been confirmed in the neurons of AD brains. This may be due to severe impairment of the clearance of damaged mitochondria (such as through mitophagy) [89,90]. Mitophagy dysfunction can cause the accumulation of autophagic vacuoles (AVs) in neuronal cell bodies. AVs contain a large number of Aβ polypeptides, and they are a location where Aβ easily forms aggregates [91]. In AD patients, we found that Parkin and PINK1 are reduced, which decreases the occurrence of mitophagy, and the damaged mitochondria cannot be cleared [92], causing a dysfunction of mitochondrial transport, hyperphosphorylation of tau protein, and synaptic dysfunction [93].

Aβ/tau is also involved in mitochondrial dysfunction in AD. Overexpression of APP in the neurons leads to mitochondrial dysfunction [89]. Aβ and P-tau can directly interact with mitochondrial components, such as VDAC1 and Complex IV, and interfere with their function [94,95,96]. Mitochondrial dysfunction has been found in AD patients and mouse models; specifically, mitochondrial membrane potential is decreased, ROS production is increased, and mitochondrial swelling occurs [97,98,99]. In an AD cell model, mitofusin 1/2 (MFN1/2) decreased and Aβ oligomers induced mitochondrial fragmentation. Further studies have shown that Aβ oligomer mediates the activation of dynamin-related protein 1 (Drp1); this mitochondrial division proteins cause mitochondrial fragmentation and cell death in AD patients [100]. In addition, extracytoplasmic calcium is harmful to neurons and its presence may lead to neuronal death [101]. The endoplasmic reticulum and mitochondria are the main locations where intracellular calcium is stored, and they play a key role in intracellular calcium homeostasis [102,103]. It has been reported that Aβ oligomers disrupt intracellular calcium homeostasis. Aβ enhances glutamate neurotransmission and increases tau phosphorylation through n-methyl-D-aspartate receptors (NM-DARs), resulting in impaired mitochondrial function [104,105,106]. Tau pathology is also involved in AD mitochondrial dysfunction [107,108,109,110,111,112,113,114]. Studies have reported that P-tau leads to downregulation of Optic Atrophy 1 (Opa1) and Drp1. In addition, P-tau may cause an increase in mitochondrial membrane potential, thereby preventing the mitochondrial recruitment of Parkin by PINK1 [107,115,116,117]. In AD, hyperphosphorylation of tau can influence tau’s ability to bind to microtubules and can disrupt mitochondrial axon transport [118,119]. Mitochondrial fusion gene mutations have been shown to lead to mitochondrial fragmentation and AD pathology [120]. In addition, an inhibitor of mitochondrial Complex I induced tau protein pathology in rats [121,122]. Studies have shown that oxidative stress increases γ-secretase activity [123]. Similarly, excessive ROS promotes P-tau aggregation through phospholipid peroxidation [124,125]. Therefore, the accumulation of Aβ and p-tau proteins can aggravate mitochondrial dysfunction, and mitochondrial dysfunction can also aggravate tau phosphorylation and Aβ aggregation. In fact, there may be a vicious cycle between mitochondrial dysfunction and AD pathology. Figure 2 illustrates the key events in mitophagy as it relates to AD.

4. Reticulophagy

The endoplasmic reticulum (ER) is a network that is responsible for lipid and protein biosynthesis, and the modification and folding of secreted proteins. There are two vital quality control mechanisms in the cell, namely the unfolded protein response (UPR) and the ER-associated degradation pathways (ERAD) [126,127]. Activation of UPR has been reported to induce the formation of ER-associated autophagosomes, which can specifically wrap the ER and then fuse with the lysosome for degradation [128,129]. Reticulophagy seems to coexist with the downstream signaling pathways of ER stress, balancing the expansion of the ER [130,131,132]. Studies have shown that a PS1 mutation inhibits IRE1 signaling. IRE1 is an ER stress sensor serine/threonine kinase involved in AD pathogenesis, in which the IRE1α/JKN pathway may predispose a subject towards amyloid deposition and the process of AD [133,134]. Transcription factor XBP1 can bind to the promoter region of γ-secretase complex (Psen1 and Ncstn), which play an important role in Aβ synthesis [135]. Studies have shown that phospho-PERK increased in AD patients and that PS1 mutants inhibited PERK signaling [133,136]. Several receptors of reticulophagy have been discovered: FAM134, SEC62, RTN3, and CCPG1. RTN3 is involved in the development of neurodegenerative diseases [32]. RTN3 has several cleavage isoforms, the longest of which has six LIR domains that can bind with LC3/GABARAP and enhance the segmentation of ER tubules, inducing reticulophagy. In fact, RTN3 mainly initiates reticulophagy under conditions of deficient energy or hypoxia. RTN3 is a protein containing RHD that is located in the ER tubules, and its main function is to promote the formation of more ER tubules [137]. RTN3 was initially identified as a negative regulator of BACE1. BACE1 is an enzyme that cleaves APP to release beta-amyloid peptides. Increased RTN3 monomer expression affects the intracellular transport of BACE1, resulting in more BACE1 being retained in the ER, where the cleavage capacity of BACE1 for APP is attenuated. Interestingly, RTN3 can form aggregates, and an increase in the number of aggregates of RTN3 appears to be related to the formation of RTN3 immunoreactive dystrophic neurites in AD patients’ brains. Therefore, RTN3 aggregation counteracts the normal function of RTN3, by negatively regulating the RTN3 monomer-mediated BACE1 activity [32].

Growing evidence has suggested that UPR activation markers are increased in AD patients’ brains and animal models [136,138]. Studies have shown that the deposition of Aβ attenuates the interaction of the ER and microtubules in the hippocampal neurons, leading to the activation of reticulophagy [139]. In addition, chemicals that interfere with the cholesterol metabolism in the ER have been reported to increase the clearance of Aβ42, further suggesting that ER dysfunction is closely related to AD [140]. In addition, ER stress triggers autophagy, greatly decreasing APP and amyloid beta precursor-like protein 1 (APLP1). The inhibition of autophagy contributes to the deposition of APP and APLP1 [29]. Furthermore, tau has contributed to our understanding of the relationship between ER and autophagy. A study found that ER stress induces autophagy to reduce the deleterious effects of tau [141]. Therefore, the relationship between reticulophagy and AD needs further exploration. Figure 3 depicts the mechanism by which reticulophagy appears to be involved in aging and AD.

5. Lipophagys

Lipid droplets (LDs) are organelles that store lipid. Mitochondria and the ER respond to ER stress and provide mitochondrial energy [142]. Lipophagy is a subtype of selective autophagy that targets LDs for degradation and plays a role in regulating lipid storage. In lipophagy, LC3-positive phagocytes engulf LDs and gradually form autophagosomes, fusing with lysosomes and degrading to glycerol and free fatty acids. Different LD-resident proteins participate in targeting LDs to undergo lipophagy, including the molecular chaperones, the Rab molecular switch family, and the UPS system [143]. In addition, adipose triglyceride lipase (ATGL) has been demonstrated to regulate lipophagy by interacting with LC3 [144]. LDs can be directly targeted for degradation by lysosomes. Furthermore, the LD-associated protein perilipins can be degraded by CMA, making LDs more susceptible to lipophagy and lipolytic degradation [145].

Many studies have shown that there is a relationship between AD and autophagy. The accumulation of LDs has been detected in mouse models of AD and the human brain [146]. There is ample evidence that LD accumulation is correlated with the pathology and severity of AD. When neurons are overactive or undergo oxidative stress, LDs accumulate in the neurons and are then transported to the astrocytes for degradation [147]. Interestingly, LD accumulation in the astrocytes has been shown to reduce the impact of ROS, thereby providing an antioxidant defense mechanism [148]. Similarly, the increased ROS production caused by neuronal dysfunction promotes the accumulation of LD in the microglia [149]. Although LDs in the microglia were initially thought to have a protective effect, it has been shown that an accumulation of LDs in the microglia can induce oxidative stress in mouse models [150]. Providing further evidence for the destructive role of LD accumulation in AD, studies have shown that cholesteryl esters in LDs reduce proteasome activity, therefore promoting the accumulation of P-tau [33]. Furthermore, studies have shown that the accumulation of LDs in AD mouse models inhibits the regenerative and homeostatic functions of neural stem cells [146]. There are a large number of LDs in neurons, and the normal metabolism of these lipids is essential for maintaining healthy neuronal function. Several studies have shown that a reduction in the cholesterol content of neurons greatly affects neuronal activity and neurotransmission, resulting in progressive degeneration of dendritic spines and synapses, which is the main characteristic of AD pathogenesis [151,152,153]. Furthermore, sphingomyelinase has been shown to increase neuronal apoptosis by producing the pro-apoptotic molecule ceramide [154,155,156]. Therefore, given the critical role of LD accumulation in AD pathology, lipophagy may represent a novel therapeutic strategy. Indeed, choline supplementation has been explored as a novel AD therapy [157]. Given this evidence, further investigation of the relationship between lipophagy and AD is warranted.

6. Pexophagy

Peroxisome dysfunction appears to be associated with many neurodegenerative diseases, including AD and Parkinson’s disease (PD) [158]. Peroxisomes include enzymes such as catalase (which can break down ROS), glutathione peroxidase (which breaks down hydrogen peroxide), and superoxide dismutase (which breaks down superoxide) [159]. Furthermore, they have been implicated in adipogenesis and ROS signaling in the heart and gut [160,161]. In particular, peroxisomes synthesize the lipids that make up myelin sheaths, cell membranes, and other phospholipids in the neurons. Peroxisome dysfunction impairs neuronal migration and cell membrane synthesis [162,163,164,165].

Pexophagy refers to selective degradation of the peroxisomes by autophagy. Thus, it controls the quality of the peroxisomes [166]. However, pexophagy-specific receptors have not been well studied in mammalian cells. Pexophagy mainly relies on the ubiquitination of peroxisomal proteins in mammals [167,168]. Studies have shown that overexpression of NBR1 and p62 induces peroxisome clustering and degradation. P62 is indispensable for pexophagy, whereas NBR1 overexpression manifests as hyperactivation of pexophagy. p62-NBR1 binding increases the efficiency of NBR1-mediated pexophagy [167]. Studies have shown that peroxisomal biogenesis factor 5 (PEX5) must be ubiquitinated by peroxisomal biogenesis factor (PEX2), an E3 ubiquitin ligase, to initiate mammalian pexophagy. However, a recent study suggested that increased cytoplasmic ROS can stimulate ubiquitination, allowing PEX5 to act as a ROS sensor, subsequently causing pexophagy [168,169,170]. After PEX5 is ubiquitinated, it is recognized by NBR1 or p62, which binds to the autophagosome, and pexophagy occurs [43,167,171].

In certain neurodegenerative diseases, the number and function of peroxisomes may be impaired. In AD, Aβ and tau proteins aggregate in the neurons, and the peroxisomes may be affected. One study has shown that treatment with a peroxisome proliferator, Wy-14.463, in an Aβ overexpressing rat hippocampus, increased peroxidase numbers and catalase activity, reduced ROS production, and produced the denaturing effects of beta-amyloid [172]. In a clinical study, plasma glycogen decreased in postmortem brain samples from AD patients, indicating reduced peroxisome activity or a shortened half-life of plasmalogens [173]. Abnormally reactive peroxisomes lead to excess ROS production, which, in turn, leads to activation of ATM kinase, which promotes phosphorylation and subsequent autoubiquitination of PEX5 to initiate pexophagy [169]. Therefore, as an important mechanism of neurodegenerative diseases, pexophagy may be beneficial in neurodegenerative diseases. However, there is no direct evidence that pexophagy and AD are related. Another gap in the literature is that there are no sex- or age-related studies on peroxisomes in neurological disorders. For example, there are studies on sex differences in response to cerebral ischemia or ischemic stroke, but it is unclear how these sex-related differences specifically affect peroxisomes [174,175,176]. Considering the effects of the peroxisome in the brain, future research on age-related neurological changes should investigate how the peroxisome pathways are affected, particularly in AD.

7. Nucleophagy

Nucleophagy refers to the selective removal of nuclear components by autophagy [177,178]. Mutations in Lamin A/C and Emerin lead to the formation of giant autophagosomes for the clearance of damaged nuclear material, thereby causing envelopathy [179]. The degradation of LMNB1 (Lamin B1) and chromatin during oncogene-induced human cell senescence is mediated by autophagy directly interacting with MAP1LC3B, suggesting the existence of a protective mechanism against tumors [180]. Although there is no evidence of a link between nucleophagy and AD, studies have found that LMNB1 mutation causes human degenerative disease and adult demyelinating leukodystrophy, and that LMNB1 and MAP1LC3B must interact for nucleophagy to occur [180,181,182]. Activation of LMNB1 can significantly delay cell senescence and alleviate degenerative diseases, suggesting that LMNB1-induced nucleophagy may have a protective effect [183,184,185].

8. Lysophagy

Lysophagy refers to damaged lysosomes being encapsulated by autophagosomes and fused with healthy lysosomes through autophagy. At the same time, β-galactoside is released from the damaged lysosome and is sensed by LGALS3/GAL3 (galectin 3), a key marker of lysosomal phagocytosis [186]. In addition, TRIM16, the E3 ligase of the TRIM family, is recruited to LGALS3 and localized to the damaged lysosomes, where it is further ubiquitinated to initiate autophagy, thereby removing the damaged lysosomes [187,188]. Similar to other types of organelle-selective autophagy, it relies on the degradation of p62-MAP1LC3B ubiquitination [186,189]. A novel ubiquitinated glycoprotein, FBXO27, also regulates impaired lysosomal recruitment [190]. In AD models, when lysophagy is damaged, the accumulated proteins cannot be cleared in a timely manner, which aggravates the symptoms of AD. It has been found that Aβ promotes the activation of NLRP3 inflammasomes by inducing lysosomal leakage; this indicates that lysosomal abnormalities in AD lead to inflammatory responses [191]. Moreover, lysosomal dysfunction can lead to neurodegeneration, and some lysosome-related gene mutations, such as valosin-containing protein (VCP), p62, OPTN, or TBK1, can cause lysosomal damage. These mutations have also been confirmed to be involved in the pathogenesis of neurodegenerative diseases [192,193,194]. Therefore, quality control of the lysosomes is crucial in neurodegenerative diseases.

9. Ribophagy

Ribosomes are the main organelles responsible for protein synthesis and translation; hence, they are crucial to cell homeostasis [195]. Generally, ribosome turnover in the cell is controlled by a selective autophagy process, known as ribophagy. Studies have shown that, in yeast, the ubiquitin protease ubiquitin carboxyl-terminal hydrolase 3 (UBP3) and its cofactor, UBP3-associated protein BRE5 (Bre5), participate in this process, which mainly targets the 60S subunit but does not affect the 40S subunit [196]. The recent discovery that USP10 and G3BP1 are homologous genes of UBP3 and Bre5 in mammals suggests that ribophagy is evolutionarily conserved [197]. There is increasing evidence that in mammalian cells, ribosomes are consumed by autophagosomes. Ribosomes are also involved in neurodegeneration, indicating that ribophagy plays a key role in cell function and vitality [198]. Studies have shown that during nutrient starvation, NUFIP1, an LIR motif-containing ribosome receptor, binds to LC3B on autophagosomes, mediates ribosome turnover, and promotes cell survival.

10. Therapeutic Strategies for AD Based on Selective Autophagy

Although the detailed mechanism(s) of selective autophagy in AD remains to be elucidated, enhancing autophagy by genetic manipulation or pharmacological approaches has been beneficial in different AD models. Overexpression of PINK1 restores mitochondrial function, reduces Aβ production and amyloid pathology, and attenuates synaptic and cognitive function by activating mitophagy signaling in APP transgenic mice [199]. In addition, AD is an aging-related disease and aging damages organelles, especially the mitochondria, causing the accumulation of abnormal proteins that damage the quality control of organelles. This undoubtedly plays a great role in the survival and function of neurons, and the clearance of these damaged organelles and proteins will benefit neuron homeostasis. PPAR/PPARα is a transcription factor that regulates neural autophagy in the system, and its mediated autophagy can affect AD. In one study, its agonist, Wy14643, was found to activate autophagy, reduce Aβ protein levels, and treat cognitive impairment in AD mice [200]. In this process, PPAR/PPARα is a peroxisome-related receptor, but it can regulate lipid metabolism-related genes, thereby regulating autophagy in the nervous system, which indicates that in cells, there is a crosslink between different organelles. In AD mice and nematode models, mitochondrial stimuli, such as NAD+ supplementation, urolithin A, and actinonin, increased PINK1 and Parkin-dependent mitophagy and alleviated AD pathology, suggesting that the removal of damaged mitochondria can act as a potential therapeutic strategy [201]. Furthermore, studies have found that microRNA can treat AD by enhancing autophagy and improving synaptic function [202]. However, it is not clear whether these microRNA participate in selective autophagy. Moreover, in the latest research, it was found that damage to the lysosome can cause synaptic dysfunction, which can cause nervous system-related diseases [203]. Lysosomes are the most critical degradation centers for all kinds of autophagy, so clearing damaged lysosomes and maintain healthy lysophagy quality will play an important role in AD treatment. A study found that impaired CMA caused neuronal dysfunction, increased protein toxicity, and neurological disorders, while chemical enhancement of CMA delayed the onset of AD in mice model [204]. This also implies that we can analyze its structure and function according to the CMA-specific receptors, find specific targets, conduct drug development, and specifically enhance the function of the CMA, which is a strategy for treating AD.

11. Discussion

Current studies have indicated that multiple autophagies may together contribute to the pathogenesis of AD. An increase in aggregating proteins will cause cytotoxicity and damage mitophagy, while damage to the mitochondria will aggravate the pathology of AD, forming a vicious cycle and causing damage to the body. Impaired mitochondrial function can also lead to changes in other organelles, such as reduced energy synthesis, reduced endoplasmic reticulum protein processing, and decreased synthesis of degrading enzymes, resulting in the accumulation of damaged proteins [205]. Studies have found that reticulophagy may play a protective role in AD patients, and the accumulation of toxic proteins can lead to positive feedback regulation of the ER, which degrades the damaged ER and misfolded proteins through macroautophagy and CMA.

In the subtypes of selective autophagy, the identification of AD-related specific receptors is a big challenge. For aggrephagy, several receptors have been confirmed, such as p62, NBR1, ALFY, and OPTN [206]. However, we need to further determine whether the degradation of Aβ and PHF-tau aggregates, and TNF are receptor-specific. If so, drugs that target specific receptors can be discovered and studied to promote degradation, which would then become a viable strategy for treating AD. For mitophagy, post-translational modifications (PTMs) are regarded as a key mechanism [207]. In addition, PINK1, BNIP3L, BNIP3, FUNDC1, NIPSNAP1, NIPSNAP2, BCL2L13, prohibitin 2, MCL-1, OPTN, and FKBP prolyl isomerase 8 (FKBP8) [208,209] have been identified as receptors. However, only a few receptors have been reported to be involved in the pathogenesis of AD. Are there other mitophagy receptors that mediate the clearance of damaged mitochondria in AD? With regard to reticulophagy and lipophagy, while there is very little evidence of their involvement in the pathogenesis of AD, ER stress, ER injury, and mutations in the reticulophagy-related receptor RTN3 have been demonstrated to be associated with AD pathogenesis [210]. Enhanced lipophagy can reduce the accumulation of lipid droplets and thereby reduce the neuronal neurodegeneration caused by an accumulation of dihydroceramide desaturase [211]. Therefore, more evidence is needed to support the involvement of reticulophagy and lipophagy in the pathogenesis of AD. Overall, the discovery of specific clearance mechanisms for these damaged organelles will provide new targets for the treatment of AD. Here, we have listed the related receptors in selective autophagy in AD (Table 1).

In macroautophagy, substrates are recognized by different receptors in different selective autophagy pathways for degradation. Furthermore, at least 30% of the protein degradation process is through CMA, which is also lysosome-dependent and highly selective. The misfolded protein is further identified by Hsc70 by attaching a KFERQ motif, and is degraded by the lysosomal receptor Lamp2A. How does the cell recognize and maintain its specificity? This needs to be studied further, but it gives us a new way to focus on the receptor. Is it the structure of the receptor that determines this process and is there a propensity to degrade the damaged protein under certain conditions? In one recent study, APP protein was found to be the receptor of CMA [240], and APP could conduct both macroautophagy and CMA. However, how to conduct macroautophagy and CMA, and whether there is a priority between the two are problems to be solved in the future.

Finding the specific receptors will be the key point for promoting selective autophagy in AD. Therefore, further studies to find other autophagy-related receptors, develop specific drugs, or discover crosslinks between different subtypes of selective autophagy should provide new approaches for the treatment of AD.

Acknowledgments

We would like to thank Carol Chu for her enormous support in ordering reagents and managing our lab needs. We would also like to thank Martha Dahlen for English editing. Figures were created with BioRender (https://biorender.com, accessed on 20 March 2022).

Author Contributions

The research study was conceived and conceptualized, and funding was obtained by K.-H.C., M.L. and J.T.; manuscript drafting, literature collection, and manuscript editing: X.G., A.I., S.G.S. and C.S. Z.Z., J.L. (Jia Liu), Y.K., A.I. and S.G.S. helped organize the manuscript and provided technical support. Manuscript review and editing: A.I., S.G.S., J.L. (Jiahong Lu), J.T. and M.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Shenzhen Science and Technology Innovation Commission, grant number (JCYJ20180302174028790, JCYJ20180507184656626); the Hong Kong Baptist University, grant number (HKBU/RC-IRCs/17-18/03, IRCMS/19-20/H02); the National Natural Science Foundation of China, grant number (81703487, 81773926); the Hong Kong Health and Medical Research Fund, grant number (HMRF17182541, HMRF17182551, HMRF 19200721); the National Natural Science Foundation of China, grant number (82171258); the Department of Science and Technology of Hunan Province, grant number (the Innovative Team Program 2019RS1010); Central South University, grant number (the Innovation-Driven Team Project 2020CX016); Hong Kong General Research Fund, grant number (GRF/HKBU12100618).

Conflicts of Interest

The authors declare that they have no conflict of interest.

Abbreviations

AD	Alzheimer’s disease	
Aβ	amyloid β-protein	
APP	amyloid precursor protein	
Atg8	autophagy-related protein 8	
AVs	autophagic vacuoles	
APLP1	amyloid beta precursor-like protein 1	
Atg39	autophagy-related protein 39	
ALFY	WD repeat and FYVE domain containing 3	
ATGL	adipose triglyceride lipase	
ATM	ataxia-telangiectasia mutated	
BNIP3	E1B 19 kDa protein-interacting protein 3	
BNIP3L	adenovirus E1B 19kDa interacting protein 3-like	
Bre5	UBP3-associated protein BRE5	
BACE1	beta-site APP-cleaving enzyme 1	
CMA	chaperone-mediated autophagy	
CHIP	C-terminus of Hsc70-interacting protein	
CCPG1	cell cycle progression protein 1	
ER	endoplasmic reticulum	
ERAD	ER-associated degradation	
FIP200	focal adhesion kinase family-interacting protein of 200 kDa	
FBXO27	F-box protein	
FKBP8	FKBP prolyl isomerase 8	
G3BP1	G3BP stress granule assembly factor 1	
Galectin 3	LGALS3/GAL3	
TRIM16	tripartite motif containing 16	
HDAC6	histone deacetylase 6	
Hsc70	heat shock cognate protein 70	
HSP60	heat shock cognate protein 60	
HSP90	heat shock cognate protein 90	
HSPs	heat shock proteins	
LDs	lipid droplets	
LMNB1	lamin B1 protein	
LC3	microtubule-associated proteins light chain 3	
MFN1/2	mitofusin 1 and 2	
Drp1	dynamin-related protein 1	
NUFIP1	nuclear fragile X mental retardation-interacting protein 1	
NM-DARS	n-methyl-D-aspartate receptors	
NFTs	neurofibrillary tangles	
Nvj1	nucleus–vacuole junction protein 1	
NBR1	neighbor of BRCA1 gene 1	
NLRP3	NLR family pyrin domain containing 3	
Opa1	optic atrophy 1	
PHFs	paired helical filaments	
PINK1	PTEN-induced kinase 1	
PGC-1-alpha	peroxisome proliferator-activated receptor gamma coactivator 1	
PTMs	post-translational modifications	
PEX5	peroxisomal biogenesis factor 5	
PEX2	peroxisomal biogenesis factor 2	
PD	Parkinson’s disease	
PPAR/PPARα	peroxisome proliferator activated receptor alpha	
PI3P	phosphatidylinositol 3-phosphate	
P-tau	phosphorylated tau	
ROS	reactive oxygen species	
RTN3	reticulon 3	
P62	SQSTM1-p62	
SEC62	preprotein translocation factor	
RB1CC1	RB1-inducible coiled-coil 1	
TBK1	serine/threonine protein kinase	
TCA	tricarboxylic acid cycle	
UPS	ubiquitin–proteasome system	
UBA	ubiquitin-associated domains	
UCHL1	ubiquitin carboxyl-terminal hydrolase L1	
ULK1	Unc-51-like autophagy activating kinase 1	
UBP3	ubiquitin carboxyl-terminal hydrolase 3	
USP10	ubiquitin-specific protease 10	
UPR	unfolding protein response	
VDAC1	voltage-dependent anion-selective channel 1	
VPS34	vacuolar protein sorting 34	
Vac8	vacuole related 8	
VCP	valosin-containing protein.	

Figure 1 Mechanism of aggrephagy during the occurrence of AD. (A) Polyubiquitinated Aβ plaques and fibers binds to p62 and NBR1 specifically, and initiate degradation through aggrephagy. (B) Hsc70 interacts with CHIP to regulate tau ubiquitination and then is recruited by p62. (C) All these aggregate proteins are wrapped by autophagosomes for degradation. (D) KFERQ binds with tau aggregates and is transferred to the lysosome by the Lamp2A receptor for degradation.

Figure 2 Mitophagy in the pathogenesis of AD. (A) Impairment of the mitochondria occurs in the early stages of AD, and Aβ and P-tau are increased. (B) Aβ and P-tau interact with VDAC1 and Complex IV, and interfere with mitochondrial function. (C) Aβ and P-tau induce mitochondrial fragmentation by reducing MFN1/2 and activating Drp1. (D) Hyperphosphorylation of tau blocks the binding of tau with microtubules, disrupting mitochondrial axon transport. (E) Aβ and P-tau disturb the recruitment of PINK1 and Parkin, causing mitophagy dysfunction.

Figure 3 Reticulophagy in the pathogenesis of AD. (A) RTN3 aggregation counteracts the negative regulation of BACE1 activity by RTN3, causing Aβ to increase in the aging brain. (B) Deposition of Aβ inhibits the interaction of the ER and microtubules, inducing reticulophagy. (C) ER stress/AD factors increase misfolded proteins through the IRE1 and PERK pathway. (D) KFERQ binds with impaired ER for CMA degradation. (E) Autophagosomes wrap the impaired ER for degradation.

ijms-23-03609-t001_Table 1 Table 1 List of selective autophagy receptors in the pathogenesis of AD.

Selective Autophagy	Receptor	References	AD-Related Receptor	
Aggrephagy	P62; NBR1; ALFY
Hsc70; CHIP
OPTN; TOLLIP
TAX1 binding protein 1	[38,39]
[57]
[212,213]
[214]	P62; NBR1; ALFY
Hsc70; CHIP	
Mitophagy	PINK1/Parkin
VDAC; RHOT1
MFN1/2; BNIP3L
FUNDC1; BNIP3
AMBRA1; BCL2LI3
FKBP8; CHDHD
ISC1; PHB2
Cardiolipin; NIPSNAP1/2
NDP52; OPTN
MCL-1; P62	[201,215]
[216,217]
[218,219]
[208,220]
[221,222]
[223,224]
[225,226]
[227,228]
[229,230]
[231,232]	PINK1/Parkin
MCL-1; DISC1	
Reticulophagy	FAM134B.; SEC62
CCPG1; RTN3
ATL3	[233,234]
[32,210,235]
[236]	RTN3	
Lipophagy	ATGL	[144]	-	
Pexophagy	NBR1; P62;
ABCD3	[167]
[237]	-	
Nucleophagy	Atg39	[238]	-	
Lysophagy	Galectin 3	[186]	-	
Ribophagy	NUFIP1	[239]	-	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Moreira P.I. Santos R.X. Zhu X. Lee H.G. Smith M.A. Casadesus G. Perry G. Autophagy in Alzheimer’s disease Expert Rev. Neurother. 2010 10 1209 1218 10.1586/ern.10.84 20586699
2. Querfurth H.W. LaFerla F.M. Alzheimer’s disease N. Engl. J. Med. 2010 362 329 344 10.1056/NEJMra0909142 20107219
3. Selkoe D.J. Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years EMBO Mol. Med. 2016 8 595 608 10.15252/emmm.201606210 27025652
4. Dorszewska J. Prendecki M. Oczkowska A. Dezor M. Kozubski W. Molecular Basis of Familial and Sporadic Alzheimer’s Disease Curr. Alzheimer Res. 2016 13 952 963 10.2174/1567205013666160314150501 26971934
5. Kelley B.J. Petersen R.C. Alzheimer’s disease and mild cognitive impairment Neurol. Clin. 2007 25 577 609 10.1016/j.ncl.2007.03.008 17659182
6. Thinakaran G. Koo E.H. Amyloid precursor protein trafficking, processing, and function J. Biol. Chem. 2008 283 29615 29619 10.1074/jbc.R800019200 18650430
7. Schindowski K. Bretteville A. Leroy K. Begard S. Brion J.P. Hamdane M. Buee L. Alzheimer’s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits Am. J. Pathol. 2006 169 599 616 10.2353/ajpath.2006.060002 16877359
8. Yin X. Qiu Y. Zhao C. Zhou Z. Bao J. Qian W. The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease Med. Sci. Monit. 2021 27 e933084 10.12659/MSM.933084 34471085
9. Malampati S. Song J.X. Chun-Kit Tong B. Nalluri A. Yang C.B. Wang Z. Gopalkrishnashetty Sreenivasmurthy S. Zhu Z. Liu J. Su C. Targeting Aggrephagy for the Treatment of Alzheimer’s Disease Cells 2020 9 311 10.3390/cells9020311
10. Nixon R.A. Wegiel J. Kumar A. Yu W.H. Peterhoff C. Cataldo A. Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study J. Neuropathol. Exp. Neurol. 2005 64 113 122 10.1093/jnen/64.2.113 15751225
11. Lucin K.M. O’Brien C.E. Bieri G. Czirr E. Mosher K.I. Abbey R.J. Mastroeni D.F. Rogers J. Spencer B. Masliah E. Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer’s disease Neuron 2013 79 873 886 10.1016/j.neuron.2013.06.046 24012002
12. Pickford F. Masliah E. Britschgi M. Lucin K. Narasimhan R. Jaeger P.A. Small S. Spencer B. Rockenstein E. Levine B. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice J. Clin. Investig. 2008 118 2190 2199 10.1172/JCI33585 18497889
13. Rohn T.T. Wirawan E. Brown R.J. Harris J.R. Masliah E. Vandenabeele P. Depletion of Beclin-1 due to proteolytic cleavage by caspases in the Alzheimer’s disease brain Neurobiol. Dis. 2011 43 68 78 10.1016/j.nbd.2010.11.003 21081164
14. Morel E. Chamoun Z. Lasiecka Z.M. Chan R.B. Williamson R.L. Vetanovetz C. Dall’Armi C. Simoes S. Point Du Jour K.S. McCabe B.D. Phosphatidylinositol-3-phosphate regulates sorting and processing of amyloid precursor protein through the endosomal system Nat. Commun. 2013 4 2250 10.1038/ncomms3250 23907271
15. Chung K.M. Hernandez N. Sproul A.A. Yu W.H. Alzheimer’s disease and the autophagic-lysosomal system Neurosci. Lett. 2019 697 49 58 10.1016/j.neulet.2018.05.017 29758300
16. Song J.X. Malampati S. Zeng Y. Durairajan S.S.K. Yang C.B. Tong B.C. Iyaswamy A. Shang W.B. Sreenivasmurthy S.G. Zhu Z. A small molecule transcription factor EB activator ameliorates beta-amyloid precursor protein and Tau pathology in Alzheimer’s disease models Aging Cell 2020 19 e13069 10.1111/acel.13069 31858697
17. Iyaswamy A. Krishnamoorthi S.K. Zhang H. Sreenivasmurthy S.G. Zhu Z. Liu J. Su C.F. Guan X.J. Wang Z.Y. Cheung K.H. Qingyangshen mitigates amyloid-beta and Tau aggregate defects involving PPARalpha-TFEB activation in transgenic mice of Alzheimer’s disease Phytomedicine 2021 91 153648 10.1016/j.phymed.2021.153648 34332287
18. Iyaswamy A. Krishnamoorthi S.K. Song J.X. Yang C.B. Kaliyamoorthy V. Zhang H. Sreenivasmurthy S.G. Malampati S. Wang Z.Y. Zhu Z. NeuroDefend, a novel Chinese medicine, attenuates amyloid-beta and tau pathology in experimental Alzheimer’s disease models J. Food Drug Anal. 2020 28 132 146 10.1016/j.jfda.2019.09.004 31883601
19. Sreenivasmurthy S.G. Iyaswamy A. Krishnamoorthi S. Senapati S. Malampati S. Zhu Z. Su C.F. Liu J. Guan X.J. Tong B.C. Protopine promotes the proteasomal degradation of pathological tau in Alzheimer’s disease models via HDAC6 inhibition Phytomedicine 2022 96 153887 10.1016/j.phymed.2021.153887 34936968
20. Iyaswamy A. Krishnamoorthi S.K. Liu Y.W. Song J.X. Kammala A.K. Sreenivasmurthy S.G. Malampati S. Tong B.C.K. Selvarasu K. Cheung K.H. Yuan-Hu Zhi Tong Prescription Mitigates Tau Pathology and Alleviates Memory Deficiency in the Preclinical Models of Alzheimer’s Disease Front. Pharmacol. 2020 11 584770 10.3389/fphar.2020.584770 33192524
21. Yao R.Q. Ren C. Xia Z.F. Yao Y.M. Organelle-specific autophagy in inflammatory diseases: A potential therapeutic target underlying the quality control of multiple organelles Autophagy 2021 17 385 401 10.1080/15548627.2020.1725377 32048886
22. Settembre C. Fraldi A. Medina D.L. Ballabio A. Signals from the lysosome: A control centre for cellular clearance and energy metabolism Nat. Rev. Mol. Cell Biol. 2013 14 283 296 10.1038/nrm3565 23609508
23. Jin M. Liu X. Klionsky D.J. SnapShot: Selective autophagy Cell 2013 152 368 10.1016/j.cell.2013.01.004 23332767
24. Marzella L. Ahlberg J. Glaumann H. Autophagy, heterophagy, microautophagy and crinophagy as the means for intracellular degradation Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 1981 36 219 234 10.1007/BF02912068 6116336
25. Kaushik S. Cuervo A.M. Chaperone-mediated autophagy: A unique way to enter the lysosome world Trends Cell Biol. 2012 22 407 417 10.1016/j.tcb.2012.05.006 22748206
26. Scrivo A. Bourdenx M. Pampliega O. Cuervo A.M. Selective autophagy as a potential therapeutic target for neurodegenerative disorders Lancet Neurol. 2018 17 802 815 10.1016/S1474-4422(18)30238-2 30129476
27. Sun-Wang J.L. Yarritu-Gallego A. Ivanova S. Zorzano A. The ubiquitin-proteasome system and autophagy: Self-digestion for metabolic health Trends Endocrinol. Metab. 2021 32 594 608 10.1016/j.tem.2021.04.015 34034951
28. Reddy P.H. Oliver D.M. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease Cells 2019 8 488 10.3390/cells8050488
29. Zhou F. van Laar T. Huang H. Zhang L. APP and APLP1 are degraded through autophagy in response to proteasome inhibition in neuronal cells Protein Cell 2011 2 377 383 10.1007/s13238-011-1047-9 21626267
30. Fang E.F. Mitophagy and NAD(+) inhibit Alzheimer disease Autophagy 2019 15 1112 1114 10.1080/15548627.2019.1596497 30922179
31. Nakashima A. Shima T. Tsuda S. Aoki A. Kawaguchi M. Furuta A. Yasuda I. Yoneda S. Yamaki-Ushijima A. Cheng S.B. Aggrephagy Deficiency in the Placenta: A New Pathogenesis of Preeclampsia Int. J. Mol. Sci. 2021 22 2432 10.3390/ijms22052432 33670947
32. Shi Q. Prior M. He W. Tang X. Hu X. Yan R. Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites J. Neurosci. 2009 29 9163 9173 10.1523/JNEUROSCI.5741-08.2009 19625507
33. Van der Kant R. Langness V.F. Herrera C.M. Williams D.A. Fong L.K. Leestemaker Y. Steenvoorden E. Rynearson K.D. Brouwers J.F. Helms J.B. Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-beta in iPSC-Derived Alzheimer’s Disease Neurons Cell Stem Cell 2019 24 363 375 10.1016/j.stem.2018.12.013 30686764
34. Shankar G.M. Li S. Mehta T.H. Garcia-Munoz A. Shepardson N.E. Smith I. Brett F.M. Farrell M.A. Rowan M.J. Lemere C.A. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat. Med. 2008 14 837 842 10.1038/nm1782 18568035
35. De S. Wirthensohn D.C. Flagmeier P. Hughes C. Aprile F.A. Ruggeri F.S. Whiten D.R. Emin D. Xia Z. Varela J.A. Different soluble aggregates of Abeta42 can give rise to cellular toxicity through different mechanisms Nat. Commun. 2019 10 1541 10.1038/s41467-019-09477-3 30948723
36. Fusco G. Chen S.W. Williamson P.T.F. Cascella R. Perni M. Jarvis J.A. Cecchi C. Vendruscolo M. Chiti F. Cremades N. Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers Science 2017 358 1440 1443 10.1126/science.aan6160 29242346
37. Gatica D. Lahiri V. Klionsky D.J. Cargo recognition and degradation by selective autophagy Nat. Cell Biol. 2018 20 233 242 10.1038/s41556-018-0037-z 29476151
38. Finley K.D. Edeen P.T. Cumming R.C. Mardahl-Dumesnil M.D. Taylor B.J. Rodriguez M.H. Hwang C.E. Benedetti M. McKeown M. blue cheese mutations define a novel, conserved gene involved in progressive neural degeneration J. Neurosci. 2003 23 1254 1264 10.1523/JNEUROSCI.23-04-01254.2003 12598614
39. Ramesh Babu J. Lamar Seibenhener M. Peng J. Strom A.L. Kemppainen R. Cox N. Zhu H. Wooten M.C. Diaz-Meco M.T. Moscat J. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration J. Neurochem. 2008 106 107 120 10.1111/j.1471-4159.2008.05340.x 18346206
40. Johansen T. Lamark T. Selective autophagy mediated by autophagic adapter proteins Autophagy 2011 7 279 296 10.4161/auto.7.3.14487 21189453
41. Bjorkoy G. Lamark T. Brech A. Outzen H. Perander M. Overvatn A. Stenmark H. Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death J. Cell Biol. 2005 171 603 614 10.1083/jcb.200507002 16286508
42. Ichimura Y. Kumanomidou T. Sou Y.S. Mizushima T. Ezaki J. Ueno T. Kominami E. Yamane T. Tanaka K. Komatsu M. Structural basis for sorting mechanism of p62 in selective autophagy J. Biol Chem. 2008 283 22847 22857 10.1074/jbc.M802182200 18524774
43. Kirkin V. Lamark T. Sou Y.S. Bjorkoy G. Nunn J.L. Bruun J.A. Shvets E. McEwan D.G. Clausen T.H. Wild P. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates Mol. Cell 2009 33 505 516 10.1016/j.molcel.2009.01.020 19250911
44. Pankiv S. Clausen T.H. Lamark T. Brech A. Bruun J.A. Outzen H. Overvatn A. Bjorkoy G. Johansen T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy J. Biol. Chem. 2007 282 24131 24145 10.1074/jbc.M702824200 17580304
45. Ciechanover A. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting Best Pract. Res. Clin. Haematol. 2017 30 341 355 10.1016/j.beha.2017.09.001 29156207
46. Mogk A. Bukau B. Role of sHsps in organizing cytosolic protein aggregation and disaggregation Cell Stress Chaperones 2017 22 493 502 10.1007/s12192-017-0762-4 28120291
47. Ungelenk S. Moayed F. Ho C.T. Grousl T. Scharf A. Mashaghi A. Tans S. Mayer M.P. Mogk A. Bukau B. Small heat shock proteins sequester misfolding proteins in near-native conformation for cellular protection and efficient refolding Nat. Commun. 2016 7 13673 10.1038/ncomms13673 27901028
48. Grumati P. Dikic I. Ubiquitin signaling and autophagy J. Biol. Chem. 2018 293 5404 5413 10.1074/jbc.TM117.000117 29187595
49. Peng J. Schwartz D. Elias J.E. Thoreen C.C. Cheng D. Marsischky G. Roelofs J. Finley D. Gygi S.P. A proteomics approach to understanding protein ubiquitination Nat. Biotechnol. 2003 21 921 926 10.1038/nbt849 12872131
50. Ikeda F. Dikic I. Atypical ubiquitin chains: New molecular signals. ‘Protein Modifications: Beyond the Usual Suspects’ review series EMBO Rep. 2008 9 536 542 10.1038/embor.2008.93 18516089
51. Lu M. Williamson N. Mishra A. Michel C.H. Kaminski C.F. Tunnacliffe A. Kaminski Schierle G.S. Structural progression of amyloid-beta Arctic mutant aggregation in cells revealed by multiparametric imaging J. Biol. Chem. 2019 294 1478 1487 10.1074/jbc.RA118.004511 30504224
52. Hong L. Huang H.C. Jiang Z.F. Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer’s disease Neurol. Res. 2014 36 276 282 10.1179/1743132813Y.0000000288 24512022
53. Morimoto D. Walinda E. Fukada H. Sou Y.S. Kageyama S. Hoshino M. Fujii T. Tsuchiya H. Saeki Y. Arita K. The unexpected role of polyubiquitin chains in the formation of fibrillar aggregates Nat. Commun. 2015 6 6116 10.1038/ncomms7116 25600778
54. Iqbal K. Alonso A.C. Gong C.X. Khatoon S. Pei J.J. Wang J.Z. Grundke-Iqbal I. Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles J. Neural. Transm. Suppl. 1998 53 169 180 10.1007/978-3-7091-6467-9_15 9700655
55. Brunden K.R. Trojanowski J.Q. Lee V.M. Advances in tau-focused drug discovery for Alzheimer’s disease and related tauopathies Nat. Rev. Drug Discov. 2009 8 783 793 10.1038/nrd2959 19794442
56. Guo J.L. Buist A. Soares A. Callaerts K. Calafate S. Stevenaert F. Daniels J.P. Zoll B.E. Crowe A. Brunden K.R. The Dynamics and Turnover of Tau Aggregates in Cultured Cells: Insights into Therapies for Tauopathies J. Biol. Chem. 2016 291 13175 13193 10.1074/jbc.M115.712083 27129267
57. Hatakeyama S. Matsumoto M. Kamura T. Murayama M. Chui D.H. Planel E. Takahashi R. Nakayama K.I. Takashima A. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy J. Neurochem. 2004 91 299 307 10.1111/j.1471-4159.2004.02713.x 15447663
58. Demishtein A. Fraiberg M. Berko D. Tirosh B. Elazar Z. Navon A. SQSTM1/p62-mediated autophagy compensates for loss of proteasome polyubiquitin recruiting capacity Autophagy 2017 13 1697 1708 10.1080/15548627.2017.1356549 28792301
59. Guthrie C.R. Kraemer B.C. Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes J. Mol. Neurosci. 2011 45 32 41 10.1007/s12031-011-9502-x 21340680
60. Leyk J. Goldbaum O. Noack M. Richter-Landsberg C. Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance J. Mol. Neurosci. 2015 55 1031 1046 10.1007/s12031-014-0460-y 25434725
61. Bishop P. Rocca D. Henley J.M. Ubiquitin C-terminal hydrolase L1 (UCH-L1): Structure, distribution and roles in brain function and dysfunction Biochem. J. 2016 473 2453 2462 10.1042/BCJ20160082 27515257
62. Xie M. Han Y. Yu Q. Wang X. Wang S. Liao X. UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein J. Alzheimers Dis. 2016 49 353 363 10.3233/JAD-150032 26444754
63. Yu Q. Zhang H. Li Y. Liu C. Wang S. Liao X. UCH-L1 Inhibition Suppresses tau Aggresome Formation during Proteasomal Impairment Mol. Neurobiol. 2018 55 3812 3821 10.1007/s12035-017-0558-7 28540657
64. Mattson M.P. Gleichmann M. Cheng A. Mitochondria in Neuroplasticity and Neurological Disorders Neuron 2008 60 748 766 10.1016/j.neuron.2008.10.010 19081372
65. Stockburger C. Eckert S. Eckert G.P. Friedland K. Muller W.E. Mitochondrial Function, Dynamics, and Permeability Transition: A Complex Love Triangle as A Possible Target for the Treatment of Brain Aging and Alzheimer’s Disease J. Alzheimers Dis. 2018 64 S455 S467 10.3233/JAD-179915 29504539
66. Green D.R. Van Houten B. SnapShot: Mitochondrial Quality Control Cell 2011 147 950 10.1016/j.cell.2011.10.036 22078889
67. Anzell A.R. Maizy R. Przyklenk K. Sanderson T.H. Mitochondrial Quality Control and Disease: Insights into Ischemia-Reperfusion Injury Mol. Neurobiol. 2018 55 2547 2564 10.1007/s12035-017-0503-9 28401475
68. Reddy P.H. Tripathi R. Troung Q. Tirumala K. Reddy T.P. Anekonda V. Shirendeb U.P. Calkins M.J. Reddy A.P. Mao P. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics Biochim. Biophys. Acta 2012 1822 639 649 10.1016/j.bbadis.2011.10.011 22037588
69. Santos R.X. Correia S.C. Wang X. Perry G. Smith M.A. Moreira P.I. Zhu X. A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease J. Alzheimers Dis. 2010 20 (Suppl. S2) S401 S412 10.3233/JAD-2010-100666 20463393
70. Swerdlow R.H. Khan S.M. A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease Med. Hypotheses 2004 63 8 20 10.1016/j.mehy.2003.12.045 15193340
71. Swerdlow R.H. Burns J.M. Khan S.M. The Alzheimer’s disease mitochondrial cascade hypothesis: Progress and perspectives Biochim. Biophys. Acta 2014 1842 1219 1231 10.1016/j.bbadis.2013.09.010 24071439
72. Moreira P.I. Siedlak S.L. Wang X. Santos M.S. Oliveira C.R. Tabaton M. Nunomura A. Szweda L.I. Aliev G. Smith M.A. Autophagocytosis of mitochondria is prominent in Alzheimer disease J. Neuropathol. Exp. Neurol. 2007 66 525 532 10.1097/01.jnen.0000240476.73532.b0 17549012
73. Moreira P.I. Siedlak S.L. Wang X. Santos M.S. Oliveira C.R. Tabaton M. Nunomura A. Szweda L.I. Aliev G. Smith M.A. Increased autophagic degradation of mitochondria in Alzheimer disease Autophagy 2007 3 614 615 10.4161/auto.4872 17786024
74. Hirai K. Aliev G. Nunomura A. Fujioka H. Russell R.L. Atwood C.S. Johnson A.B. Kress Y. Vinters H.V. Tabaton M. Mitochondrial abnormalities in Alzheimer’s disease J. Neurosci. 2001 21 3017 3023 10.1523/JNEUROSCI.21-09-03017.2001 11312286
75. Wang W. Yin J. Ma X. Zhao F. Siedlak S.L. Wang Z. Torres S. Fujioka H. Xu Y. Perry G. Inhibition of mitochondrial fragmentation protects against Alzheimer’s disease in rodent model Hum. Mol. Genet. 2017 26 4118 4131 10.1093/hmg/ddx299 28973308
76. Martin-Maestro P. Gargini R. Perry G. Avila J. Garcia-Escudero V. PARK2 enhancement is able to compensate mitophagy alterations found in sporadic Alzheimer’s disease Hum. Mol. Genet. 2016 25 792 806 10.1093/hmg/ddv616 26721933
77. Nguyen T.N. Padman B.S. Lazarou M. Deciphering the Molecular Signals of PINK1/Parkin Mitophagy Trends Cell Biol. 2016 26 733 744 10.1016/j.tcb.2016.05.008 27291334
78. Medala V.K. Gollapelli B. Dewanjee S. Ogunmokun G. Kandimalla R. Vallamkondu J. Mitochondrial dysfunction, mitophagy, and role of dynamin-related protein 1 in Alzheimer’s disease J. Neurosci. Res. 2021 99 1120 1135 10.1002/jnr.24781 33465841
79. Kerr J.S. Adriaanse B.A. Greig N.H. Mattson M.P. Cader M.Z. Bohr V.A. Fang E.F. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms Trends Neurosci. 2017 40 151 166 10.1016/j.tins.2017.01.002 28190529
80. Wimo A. Jonsson L. Bond J. Prince M. Winblad B. Alzheimer Disease I. The worldwide economic impact of dementia 2010 Alzheimers Dement. 2013 9 1 11 10.1016/j.jalz.2012.11.006 23305821
81. Lopez O.L. Becker J.T. Sweet R.A. Klunk W. Kaufer D.I. Saxton J. Habeych M. DeKosky S.T. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease J. Neuropsychiatry Clin. Neurosci. 2003 15 346 353 10.1176/jnp.15.3.346 12928511
82. van der Flier W.M. Scheltens P. Epidemiology and risk factors of dementia J. Neurol. Neurosurg. Psychiatry 2005 76 (Suppl. S5) v2 v7 10.1136/jnnp.2005.082867 16291918
83. Reitz C. Brayne C. Mayeux R. Epidemiology of Alzheimer disease Nat. Rev. Neurol. 2011 7 137 152 10.1038/nrneurol.2011.2 21304480
84. Kapogiannis D. Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer’s disease Lancet Neurol. 2011 10 187 198 10.1016/S1474-4422(10)70277-5 21147038
85. Dong Y. Brewer G.J. Global Metabolic Shifts in Age and Alzheimer’s Disease Mouse Brains Pivot at NAD+/NADH Redox Sites J. Alzheimers Dis. 2019 71 119 140 10.3233/JAD-190408 31356210
86. The Canadian Study of Health and Aging: Risk factors for Alzheimer’s disease in Canada Neurology 1994 44 2073 2080 10.1212/WNL.44.11.2073 7969962
87. Rona-Voros K. Weydt P. The role of PGC-1alpha in the pathogenesis of neurodegenerative disorders Curr. Drug Targets 2010 11 1262 1269 10.2174/1389450111007011262 20840068
88. Cenini G. Voos W. Mitochondria as Potential Targets in Alzheimer Disease Therapy: An Update Front. Pharmacol. 2019 10 902 10.3389/fphar.2019.00902 31507410
89. Fratiglioni L. De Ronchi D. Aguero-Torres H. Worldwide prevalence and incidence of dementia Drugs Aging 1999 15 365 375 10.2165/00002512-199915050-00004 10600044
90. Lindsay J. Hebert R. Rockwood K. The Canadian Study of Health and Aging: Risk factors for vascular dementia Stroke 1997 28 526 530 10.1161/01.STR.28.3.526 9056606
91. Hebert R. Lindsay J. Verreault R. Rockwood K. Hill G. Dubois M.F. Vascular dementia: Incidence and risk factors in the Canadian study of health and aging Stroke 2000 31 1487 1493 10.1161/01.STR.31.7.1487 10884442
92. Ye X. Sun X. Starovoytov V. Cai Q. Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer’s disease patient brains Hum. Mol. Genet. 2015 24 2938 2951 10.1093/hmg/ddv056 25678552
93. Pradeepkiran J.A. Reddy P.H. Defective mitophagy in Alzheimer’s disease Ageing Res. Rev. 2020 64 101191 10.1016/j.arr.2020.101191 33022416
94. Donix M. Ercoli L.M. Siddarth P. Brown J.A. Martin-Harris L. Burggren A.C. Miller K.J. Small G.W. Bookheimer S.Y. Influence of Alzheimer disease family history and genetic risk on cognitive performance in healthy middle-aged and older people Am. J. Geriatr. Psychiatry 2012 20 565 573 10.1097/JGP.0b013e3182107e6a 21849821
95. Pizzonia J.H. Ransom B.R. Pappas C.A. Characterization of Na+/H+ exchange activity in cultured rat hippocampal astrocytes J. Neurosci. Res. 1996 44 191 198 10.1002/(SICI)1097-4547(19960415)44:2<191::AID-JNR12>3.0.CO;2-9 8723228
96. Tiraboschi P. Hansen L.A. Masliah E. Alford M. Thal L.J. Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease Neurology 2004 62 1977 1983 10.1212/01.WNL.0000128091.92139.0F 15184600
97. Picone P. Nuzzo D. Caruana L. Scafidi V. Di Carlo M. Mitochondrial dysfunction: Different routes to Alzheimer’s disease therapy Oxid Med. Cell Longev. 2014 2014 780179 10.1155/2014/780179 25221640
98. Du H. Yan S.S. Mitochondrial permeability transition pore in Alzheimer’s disease: Cyclophilin D and amyloid beta Biochim. Biophys. Acta 2010 1802 198 204 10.1016/j.bbadis.2009.07.005 19616093
99. Rao V.K. Carlson E.A. Yan S.S. Mitochondrial permeability transition pore is a potential drug target for neurodegeneration Biochim. Biophys. Acta 2014 1842 1267 1272 10.1016/j.bbadis.2013.09.003 24055979
100. Kim D.I. Lee K.H. Gabr A.A. Choi G.E. Kim J.S. Ko S.H. Han H.J. Abeta-Induced Drp1 phosphorylation through Akt activation promotes excessive mitochondrial fission leading to neuronal apoptosis Biochim. Biophys. Acta 2016 1863 2820 2834 10.1016/j.bbamcr.2016.09.003 27599716
101. Orrenius S. Gogvadze V. Zhivotovsky B. Calcium and mitochondria in the regulation of cell death Biochem. Biophys. Res. Commun. 2015 460 72 81 10.1016/j.bbrc.2015.01.137 25998735
102. Gandhi S. Wood-Kaczmar A. Yao Z. Plun-Favreau H. Deas E. Klupsch K. Downward J. Latchman D.S. Tabrizi S.J. Wood N.W. PINK1-associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced cell death Mol. Cell 2009 33 627 638 10.1016/j.molcel.2009.02.013 19285945
103. Area-Gomez E. de Groof A. Bonilla E. Montesinos J. Tanji K. Boldogh I. Pon L. Schon E.A. A key role for MAM in mediating mitochondrial dysfunction in Alzheimer disease Cell Death Dis. 2018 9 335 10.1038/s41419-017-0215-0 29491396
104. Cheng J. Liao Y. Dong Y. Hu H. Yang N. Kong X. Li S. Li X. Guo J. Qin L. Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice Autophagy 2020 16 2193 2205 10.1080/15548627.2020.1719723 32003282
105. Zheng W.H. Bastianetto S. Mennicken F. Ma W. Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures Neuroscience 2002 115 201 211 10.1016/S0306-4522(02)00404-9 12401334
106. Garwood C.J. Pooler A.M. Atherton J. Hanger D.P. Noble W. Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture Cell Death Dis. 2011 2 e167 10.1038/cddis.2011.50 21633390
107. Perez M.J. Jara C. Quintanilla R.A. Contribution of Tau Pathology to Mitochondrial Impairment in Neurodegeneration Front. Neurosci. 2018 12 441 10.3389/fnins.2018.00441 30026680
108. Manczak M. Reddy P.H. Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage Hum. Mol. Genet. 2012 21 2538 2547 10.1093/hmg/dds072 22367970
109. Ittner L.M. Fath T. Ke Y.D. Bi M. van Eersel J. Li K.M. Gunning P. Gotz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia Proc. Natl. Acad. Sci. USA 2008 105 15997 16002 10.1073/pnas.0808084105 18832465
110. Mandelkow E.M. Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration Cold Spring Harb. Perspect. Med. 2012 2 a006247 10.1101/cshperspect.a006247 22762014
111. Kopeikina K.J. Carlson G.A. Pitstick R. Ludvigson A.E. Peters A. Luebke J.I. Koffie R.M. Frosch M.P. Hyman B.T. Spires-Jones T.L. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain Am. J. Pathol. 2011 179 2071 2082 10.1016/j.ajpath.2011.07.004 21854751
112. Andreadis A. Tau gene alternative splicing: Expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases Biochim. Biophys. Acta 2005 1739 91 103 10.1016/j.bbadis.2004.08.010 15615629
113. Leon-Espinosa G. Garcia E. Garcia-Escudero V. Hernandez F. Defelipe J. Avila J. Changes in tau phosphorylation in hibernating rodents J. Neurosci. Res. 2013 91 954 962 10.1002/jnr.23220 23606524
114. Amadoro G. Corsetti V. Stringaro A. Colone M. D’Aguanno S. Meli G. Ciotti M. Sancesario G. Cattaneo A. Bussani R. A NH2 tau fragment targets neuronal mitochondria at AD synapses: Possible implications for neurodegeneration J. Alzheimers Dis. 2010 21 445 470 10.3233/JAD-2010-100120 20571215
115. Li X.C. Hu Y. Wang Z.H. Luo Y. Zhang Y. Liu X.P. Feng Q. Wang Q. Ye K. Liu G.P. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins Sci. Rep. 2016 6 24756 10.1038/srep24756 27099072
116. DuBoff B. Gotz J. Feany M.B. Tau promotes neurodegeneration via DRP1 mislocalization in vivo Neuron 2012 75 618 632 10.1016/j.neuron.2012.06.026 22920254
117. Itoh K. Nakamura K. Iijima M. Sesaki H. Mitochondrial dynamics in neurodegeneration Trends Cell Biol. 2013 23 64 71 10.1016/j.tcb.2012.10.006 23159640
118. Crespo-Biel N. Theunis C. Van Leuven F. Protein tau: Prime cause of synaptic and neuronal degeneration in Alzheimer’s disease Int. J. Alzheimers Dis. 2012 2012 251426 10.1155/2012/251426 22720188
119. Kolarova M. Garcia-Sierra F. Bartos A. Ricny J. Ripova D. Structure and pathology of tau protein in Alzheimer disease Int. J. Alzheimers Dis. 2012 2012 731526 10.1155/2012/731526 22690349
120. Knott A.B. Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: A new mechanism of neurodegeneration Ann. N. Y. Acad. Sci. 2008 1147 283 292 10.1196/annals.1427.030 19076450
121. Hoglinger G.U. Lannuzel A. Khondiker M.E. Michel P.P. Duyckaerts C. Feger J. Champy P. Prigent A. Medja F. Lombes A. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy J. Neurochem. 2005 95 930 939 10.1111/j.1471-4159.2005.03493.x 16219024
122. Yoo S.M. Park J. Kim S.H. Jung Y.K. Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer’s disease BMB Rep. 2020 53 35 46 10.5483/BMBRep.2020.53.1.274 31818363
123. Guo L. Tian J. Du H. Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer’s Disease J. Alzheimers Dis. 2017 57 1071 1086 10.3233/JAD-160702 27662318
124. Cheng Y. Bai F. The Association of Tau With Mitochondrial Dysfunction in Alzheimer’s Disease Front. Neurosci. 2018 12 163 10.3389/fnins.2018.00163 29623026
125. Agnihotri A. Aruoma O.I. Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals J. Am. Coll Nutr. 2020 39 16 27 10.1080/07315724.2019.1683379 31829802
126. Wang S. Kaufman R.J. The impact of the unfolded protein response on human disease J. Cell Biol. 2012 197 857 867 10.1083/jcb.201110131 22733998
127. Hwang J. Qi L. Quality Control in the Endoplasmic Reticulum: Crosstalk between ERAD and UPR pathways Trends Biochem. Sci. 2018 43 593 605 10.1016/j.tibs.2018.06.005 30056836
128. Bernales S. Schuck S. Walter P. ER-phagy: Selective autophagy of the endoplasmic reticulum Autophagy 2007 3 285 287 10.4161/auto.3930 17351330
129. Khaminets A. Heinrich T. Mari M. Grumati P. Huebner A.K. Akutsu M. Liebmann L. Stolz A. Nietzsche S. Koch N. Regulation of endoplasmic reticulum turnover by selective autophagy Nature 2015 522 354 358 10.1038/nature14498 26040720
130. Bernales S. McDonald K.L. Walter P. Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response PLoS Biol. 2006 4 e423 10.1371/journal.pbio.0040423 17132049
131. Schuck S. Gallagher C.M. Walter P. ER-phagy mediates selective degradation of endoplasmic reticulum independently of the core autophagy machinery J. Cell Sci. 2014 127 4078 4088 10.1242/jcs.154716 25052096
132. Moretti J. Roy S. Bozec D. Martinez J. Chapman J.R. Ueberheide B. Lamming D.W. Chen Z.J. Horng T. Yeretssian G. STING Senses Microbial Viability to Orchestrate Stress-Mediated Autophagy of the Endoplasmic Reticulum Cell 2017 171 809 823 10.1016/j.cell.2017.09.034 29056340
133. Katayama T. Imaizumi K. Honda A. Yoneda T. Kudo T. Takeda M. Mori K. Rozmahel R. Fraser P. George-Hyslop P.S. Disturbed activation of endoplasmic reticulum stress transducers by familial Alzheimer’s disease-linked presenilin-1 mutations J. Biol. Chem. 2001 276 43446 43454 10.1074/jbc.M104096200 11551913
134. Duran-Aniotz C. Martinez G. Hetz C. Memory loss in Alzheimer’s disease: Are the alterations in the UPR network involved in the cognitive impairment? Front. Aging Neurosci. 2014 6 8 10.3389/fnagi.2014.00008 24523695
135. Acosta-Alvear D. Zhou Y. Blais A. Tsikitis M. Lents N.H. Arias C. Lennon C.J. Kluger Y. Dynlacht B.D. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks Mol. Cell 2007 27 53 66 10.1016/j.molcel.2007.06.011 17612490
136. Hoozemans J.J. van Haastert E.S. Nijholt D.A. Rozemuller A.J. Eikelenboom P. Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer’s disease hippocampus Am. J. Pathol. 2009 174 1241 1251 10.2353/ajpath.2009.080814 19264902
137. Voeltz G.K. Prinz W.A. Shibata Y. Rist J.M. Rapoport T.A. A class of membrane proteins shaping the tubular endoplasmic reticulum Cell 2006 124 573 586 10.1016/j.cell.2005.11.047 16469703
138. Hoozemans J.J. van Haastert E.S. Nijholt D.A. Rozemuller A.J. Scheper W. Activation of the unfolded protein response is an early event in Alzheimer’s and Parkinson’s disease Neurodegener. Dis. 2012 10 212 215 10.1159/000334536 22302012
139. Lai C.S. Preisler J. Baum L. Lee D.H. Ng H.K. Hugon J. So K.F. Chang R.C. Low molecular weight Abeta induces collapse of endoplasmic reticulum Mol. Cell Neurosci. 2009 41 32 43 10.1016/j.mcn.2009.01.006 19386229
140. Shibuya Y. Chang C.C. Huang L.H. Bryleva E.Y. Chang T.Y. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagy-mediated lysosomal proteolysis and increases Abeta1-42 clearance J. Neurosci. 2014 34 14484 14501 10.1523/JNEUROSCI.2567-14.2014 25339759
141. Loewen C.A. Feany M.B. The unfolded protein response protects from tau neurotoxicity in vivo PLoS ONE 2010 5 e13084 10.1371/journal.pone.0013084 20927324
142. Cohen S. Lipid Droplets as Organelles Int. Rev. Cell Mol. Biol. 2018 337 83 110 10.1016/bs.ircmb.2017.12.007 29551163
143. Robichaud S. Fairman G. Vijithakumar V. Mak E. Cook D.P. Pelletier A.R. Huard S. Vanderhyden B.C. Figeys D. Lavallee-Adam M. Identification of novel lipid droplet factors that regulate lipophagy and cholesterol efflux in macrophage foam cells Autophagy 2021 17 3671 3689 10.1080/15548627.2021.1886839 33590792
144. Martinez-Lopez N. Garcia-Macia M. Sahu S. Athonvarangkul D. Liebling E. Merlo P. Cecconi F. Schwartz G.J. Singh R. Autophagy in the CNS and Periphery Coordinate Lipophagy and Lipolysis in the Brown Adipose Tissue and Liver Cell Metab. 2016 23 113 127 10.1016/j.cmet.2015.10.008 26698918
145. Haidar M. Loix M. Bogie J.F.J. Hendriks J.J.A. Lipophagy: A new player in CNS disorders Trends Endocrinol. Metab. 2021 32 941 951 10.1016/j.tem.2021.08.010 34561114
146. Hamilton L.K. Dufresne M. Joppe S.E. Petryszyn S. Aumont A. Calon F. Barnabe-Heider F. Furtos A. Parent M. Chaurand P. Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer’s Disease Cell Stem Cell 2015 17 397 411 10.1016/j.stem.2015.08.001 26321199
147. Ioannou M.S. Jackson J. Sheu S.H. Chang C.L. Weigel A.V. Liu H. Pasolli H.A. Xu C.S. Pang S. Matthies D. Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity Cell 2019 177 1522 1535 10.1016/j.cell.2019.04.001 31130380
148. Islam A. Kagawa Y. Miyazaki H. Shil S.K. Umaru B.A. Yasumoto Y. Yamamoto Y. Owada Y. FABP7 Protects Astrocytes Against ROS Toxicity via Lipid Droplet Formation Mol. Neurobiol. 2019 56 5763 5779 10.1007/s12035-019-1489-2 30680690
149. Moreau K. Fleming A. Imarisio S. Lopez Ramirez A. Mercer J.L. Jimenez-Sanchez M. Bento C.F. Puri C. Zavodszky E. Siddiqi F. PICALM modulates autophagy activity and tau accumulation Nat. Commun. 2014 5 4998 10.1038/ncomms5998 25241929
150. Alzheimer A. Stelzmann R.A. Schnitzlein H.N. Murtagh F.R. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde” Clin. Anat. 1995 8 429 431 10.1002/ca.980080612 8713166
151. Liu Q. Trotter J. Zhang J. Peters M.M. Cheng H. Bao J. Han X. Weeber E.J. Bu G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration J. Neurosci. 2010 30 17068 17078 10.1523/JNEUROSCI.4067-10.2010 21159977
152. Liu Q. Zerbinatti C.V. Zhang J. Hoe H.S. Wang B. Cole S.L. Herz J. Muglia L. Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1 Neuron 2007 56 66 78 10.1016/j.neuron.2007.08.008 17920016
153. Linetti A. Fratangeli A. Taverna E. Valnegri P. Francolini M. Cappello V. Matteoli M. Passafaro M. Rosa P. Cholesterol reduction impairs exocytosis of synaptic vesicles J. Cell Sci. 2010 123 595 605 10.1242/jcs.060681 20103534
154. Jana A. Pahan K. Fibrillar amyloid-beta-activated human astroglia kill primary human neurons via neutral sphingomyelinase: Implications for Alzheimer’s disease J. Neurosci. 2010 30 12676 12689 10.1523/JNEUROSCI.1243-10.2010 20861373
155. Sanchez-Mejia R.O. Newman J.W. Toh S. Yu G.Q. Zhou Y. Halabisky B. Cisse M. Scearce-Levie K. Cheng I.H. Gan L. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer’s disease Nat. Neurosci. 2008 11 1311 1318 10.1038/nn.2213 18931664
156. Esposito G. Giovacchini G. Liow J.S. Bhattacharjee A.K. Greenstein D. Schapiro M. Hallett M. Herscovitch P. Eckelman W.C. Carson R.E. Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET J. Nucl. Med. 2008 49 1414 1421 10.2967/jnumed.107.049619 18703605
157. Sienski G. Narayan P. Bonner J.M. Kory N. Boland S. Arczewska A.A. Ralvenius W.T. Akay L. Lockshin E. He L. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia Sci. Transl. Med. 2021 13 eaaz4564 10.1126/scitranslmed.aaz4564 33658354
158. Cipolla C.M. Lodhi I.J. Peroxisomal Dysfunction in Age-Related Diseases Trends Endocrinol. Metab. 2017 28 297 308 10.1016/j.tem.2016.12.003 28063767
159. Nordgren M. Fransen M. Peroxisomal metabolism and oxidative stress Biochimie 2014 98 56 62 10.1016/j.biochi.2013.07.026 23933092
160. Colasante C. Chen J. Ahlemeyer B. Baumgart-Vogt E. Peroxisomes in cardiomyocytes and the peroxisome / peroxisome proliferator-activated receptor-loop Thromb. Haemost. 2015 113 452 463 10.1160/TH14-06-0497 25608554
161. Morvay P.L. Baes M. Van Veldhoven P.P. Differential activities of peroxisomes along the mouse intestinal epithelium Cell Biochem. Funct. 2017 35 144 155 10.1002/cbf.3255 28370438
162. Farooqui A.A. Horrocks L.A. Plasmalogens: Workhorse lipids of membranes in normal and injured neurons and glia Neuroscientist 2001 7 232 245 10.1177/107385840100700308 11499402
163. Powers J.M. Normal and defective neuronal membranes: Structure and function: Neuronal lesions in peroxisomal disorders J. Mol. Neurosci. 2001 16 285 287 discussion 317–321 10.1385/JMN:16:2-3:285 11478383
164. Bottelbergs A. Verheijden S. Hulshagen L. Gutmann D.H. Goebbels S. Nave K.A. Kassmann C. Baes M. Axonal integrity in the absence of functional peroxisomes from projection neurons and astrocytes Glia 2010 58 1532 1543 10.1002/glia.21027 20578053
165. Kassmann C.M. Myelin peroxisomes—Essential organelles for the maintenance of white matter in the nervous system Biochimie 2014 98 111 118 10.1016/j.biochi.2013.09.020 24120688
166. Zientara-Rytter K. Subramani S. Autophagic degradation of peroxisomes in mammals Biochem. Soc. Trans. 2016 44 431 440 10.1042/BST20150268 27068951
167. Deosaran E. Larsen K.B. Hua R. Sargent G. Wang Y. Kim S. Lamark T. Jauregui M. Law K. Lippincott-Schwartz J. NBR1 acts as an autophagy receptor for peroxisomes J. Cell Sci. 2013 126 939 952 10.1242/jcs.114819 23239026
168. Kim P.K. Hailey D.W. Mullen R.T. Lippincott-Schwartz J. Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes Proc. Natl. Acad. Sci. USA 2008 105 20567 20574 10.1073/pnas.0810611105 19074260
169. Zhang J. Tripathi D.N. Jing J. Alexander A. Kim J. Powell R.T. Dere R. Tait-Mulder J. Lee J.H. Paull T.T. ATM functions at the peroxisome to induce pexophagy in response to ROS Nat. Cell Biol. 2015 17 1259 1269 10.1038/ncb3230 26344566
170. Walton P.A. Brees C. Lismont C. Apanasets O. Fransen M. The peroxisomal import receptor PEX5 functions as a stress sensor, retaining catalase in the cytosol in times of oxidative stress Biochim. Biophys. Acta Mol. Cell Res. 2017 1864 1833 1843 10.1016/j.bbamcr.2017.07.013 28760655
171. Kabeya Y. Mizushima N. Ueno T. Yamamoto A. Kirisako T. Noda T. Kominami E. Ohsumi Y. Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing EMBO J. 2000 19 5720 5728 10.1093/emboj/19.21.5720 11060023
172. Santos M.J. Quintanilla R.A. Toro A. Grandy R. Dinamarca M.C. Godoy J.A. Inestrosa N.C. Peroxisomal proliferation protects from beta-amyloid neurodegeneration J. Biol. Chem. 2005 280 41057 41068 10.1074/jbc.M505160200 16204253
173. Goodenowe D.B. Senanayake V. Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study Brain. Sci. 2019 9 92 10.3390/brainsci9040092 31022959
174. Siegel C.S. McCullough L.D. NAD+ and nicotinamide: Sex differences in cerebral ischemia Neuroscience 2013 237 223 231 10.1016/j.neuroscience.2013.01.068 23403179
175. Mirza M.A. Ritzel R. Xu Y. McCullough L.D. Liu F. Sexually dimorphic outcomes and inflammatory responses in hypoxic-ischemic encephalopathy J. Neuroinflammation 2015 12 32 10.1186/s12974-015-0251-6 25889641
176. Ritzel R.M. Patel A.R. Spychala M. Verma R. Crapser J. Koellhoffer E.C. Schrecengost A. Jellison E.R. Zhu L. Venna V.R. Multiparity improves outcomes after cerebral ischemia in female mice despite features of increased metabovascular risk Proc. Natl. Acad. Sci. USA 2017 114 E5673 E5682 10.1073/pnas.1607002114 28645895
177. Kvam E. Goldfarb D.S. Nucleus-vacuole junctions and piecemeal microautophagy of the nucleus in S. cerevisiae Autophagy 2007 3 85 92 10.4161/auto.3586 17204844
178. Kraft C. Reggiori F. Peter M. Selective types of autophagy in yeast Biochim. Biophys. Acta 2009 1793 1404 1412 10.1016/j.bbamcr.2009.02.006 19264099
179. Park Y.E. Hayashi Y.K. Bonne G. Arimura T. Noguchi S. Nonaka I. Nishino I. Autophagic degradation of nuclear components in mammalian cells Autophagy 2009 5 795 804 10.4161/auto.8901 19550147
180. Dou Z. Xu C. Donahue G. Shimi T. Pan J.A. Zhu J. Ivanov A. Capell B.C. Drake A.M. Shah P.P. Autophagy mediates degradation of nuclear lamina Nature 2015 527 105 109 10.1038/nature15548 26524528
181. Salama R. Sadaie M. Hoare M. Narita M. Cellular senescence and its effector programs Genes Dev. 2014 28 99 114 10.1101/gad.235184.113 24449267
182. Dobrzynska A. Gonzalo S. Shanahan C. Askjaer P. The nuclear lamina in health and disease Nucleus 2016 7 233 248 10.1080/19491034.2016.1183848 27158763
183. Shimi T. Butin-Israeli V. Adam S.A. Hamanaka R.B. Goldman A.E. Lucas C.A. Shumaker D.K. Kosak S.T. Chandel N.S. Goldman R.D. The role of nuclear lamin B1 in cell proliferation and senescence Genes Dev. 2011 25 2579 2593 10.1101/gad.179515.111 22155925
184. Shah P.P. Donahue G. Otte G.L. Capell B.C. Nelson D.M. Cao K. Aggarwala V. Cruickshanks H.A. Rai T.S. McBryan T. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape Genes Dev. 2013 27 1787 1799 10.1101/gad.223834.113 23934658
185. Lukasova E. Kovarik A. Bacikova A. Falk M. Kozubek S. Loss of lamin B receptor is necessary to induce cellular senescence Biochem. J. 2017 474 281 300 10.1042/BCJ20160459 27760841
186. Maejima I. Takahashi A. Omori H. Kimura T. Takabatake Y. Saitoh T. Yamamoto A. Hamasaki M. Noda T. Isaka Y. Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury EMBO J. 2013 32 2336 2347 10.1038/emboj.2013.171 23921551
187. Chauhan S. Kumar S. Jain A. Ponpuak M. Mudd M.H. Kimura T. Choi S.W. Peters R. Mandell M. Bruun J.A. TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis Dev. Cell 2016 39 13 27 10.1016/j.devcel.2016.08.003 27693506
188. Fraiberg M. Elazar Z. A TRIM16-Galactin3 Complex Mediates Autophagy of Damaged Endomembranes Dev. Cell 2016 39 1 2 10.1016/j.devcel.2016.09.025 27728777
189. Hung Y.H. Chen L.M. Yang J.Y. Yang W.Y. Spatiotemporally controlled induction of autophagy-mediated lysosome turnover Nat. Commun. 2013 4 2111 10.1038/ncomms3111 23817530
190. Yoshida Y. Yasuda S. Fujita T. Hamasaki M. Murakami A. Kawawaki J. Iwai K. Saeki Y. Yoshimori T. Matsuda N. Ubiquitination of exposed glycoproteins by SCF(FBXO27) directs damaged lysosomes for autophagy Proc. Natl. Acad. Sci. USA 2017 114 8574 8579 10.1073/pnas.1702615114 28743755
191. Heneka M.T. Kummer M.P. Stutz A. Delekate A. Schwartz S. Vieira-Saecker A. Griep A. Axt D. Remus A. Tzeng T.C. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice Nature 2013 493 674 678 10.1038/nature11729 23254930
192. Teyssou E. Takeda T. Lebon V. Boillee S. Doukoure B. Bataillon G. Sazdovitch V. Cazeneuve C. Meininger V. LeGuern E. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: Genetics and neuropathology Acta Neuropathol. 2013 125 511 522 10.1007/s00401-013-1090-0 23417734
193. Maruyama H. Morino H. Ito H. Izumi Y. Kato H. Watanabe Y. Kinoshita Y. Kamada M. Nodera H. Suzuki H. Mutations of optineurin in amyotrophic lateral sclerosis Nature 2010 465 223 226 10.1038/nature08971 20428114
194. Freischmidt A. Wieland T. Richter B. Ruf W. Schaeffer V. Muller K. Marroquin N. Nordin F. Hubers A. Weydt P. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia Nat. Neurosci. 2015 18 631 636 10.1038/nn.4000 25803835
195. Warner J.R. The economics of ribosome biosynthesis in yeast Trends Biochem. Sci. 1999 24 437 440 10.1016/S0968-0004(99)01460-7 10542411
196. Kraft C. Deplazes A. Sohrmann M. Peter M. Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the Ubp3p/Bre5p ubiquitin protease Nat. Cell Biol. 2008 10 602 610 10.1038/ncb1723 18391941
197. Soncini C. Berdo I. Draetta G. Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease Oncogene 2001 20 3869 3879 10.1038/sj.onc.1204553 11439350
198. Baltanas F.C. Casafont I. Weruaga E. Alonso J.R. Berciano M.T. Lafarga M. Nucleolar disruption and cajal body disassembly are nuclear hallmarks of DNA damage-induced neurodegeneration in purkinje cells Brain Pathol. 2011 21 374 388 10.1111/j.1750-3639.2010.00461.x 21054627
199. Du F. Yu Q. Yan S. Hu G. Lue L.F. Walker D.G. Wu L. Yan S.F. Tieu K. Yan S.S. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease Brain 2017 140 3233 3251 10.1093/brain/awx258 29077793
200. Luo R. Su L.Y. Li G. Yang J. Liu Q. Yang L.X. Zhang D.F. Zhou H. Xu M. Fan Y. Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model Autophagy 2020 16 52 69 10.1080/15548627.2019.1596488 30898012
201. Fang E.F. Hou Y. Palikaras K. Adriaanse B.A. Kerr J.S. Yang B. Lautrup S. Hasan-Olive M.M. Caponio D. Dan X. Mitophagy inhibits amyloid-beta and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease Nat. Neurosci. 2019 22 401 412 10.1038/s41593-018-0332-9 30742114
202. Chen M.L. Hong C.G. Yue T. Li H.M. Duan R. Hu W.B. Cao J. Wang Z.X. Chen C.Y. Hu X.K. Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer’s disease by enhancing autophagy Theranostics 2021 11 2395 2409 10.7150/thno.47408 33500732
203. Zhang X. Wei M. Fan J. Yan W. Zha X. Song H. Wan R. Yin Y. Wang W. Ischemia-induced upregulation of autophagy preludes dysfunctional lysosomal storage and associated synaptic impairments in neurons Autophagy 2021 17 1519 1542 10.1080/15548627.2020.1840796 33111641
204. Bourdenx M. Martin-Segura A. Scrivo A. Rodriguez-Navarro J.A. Kaushik S. Tasset I. Diaz A. Storm N.J. Xin Q. Juste Y.R. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome Cell 2021 184 2696 2714.e2625 10.1016/j.cell.2021.03.048 33891876
205. Martinez J. Marmisolle I. Tarallo D. Quijano C. Mitochondrial Bioenergetics and Dynamics in Secretion Processes Front. Endocrinol. 2020 11 319 10.3389/fendo.2020.00319
206. Zellner S. Schifferer M. Behrends C. Systematically defining selective autophagy receptor-specific cargo using autophagosome content profiling Mol. Cell 2021 81 1337 1354 e1338 10.1016/j.molcel.2021.01.009 33545068
207. Wang L. Qi H. Tang Y. Shen H.M. Post-translational Modifications of Key Machinery in the Control of Mitophagy Trends Biochem. Sci. 2020 45 58 75 10.1016/j.tibs.2019.08.002 31606339
208. Liu L. Feng D. Chen G. Chen M. Zheng Q. Song P. Ma Q. Zhu C. Wang R. Qi W. Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells Nat. Cell Biol. 2012 14 177 185 10.1038/ncb2422 22267086
209. Xie Y. Liu J. Kang R. Tang D. Mitophagy Receptors in Tumor Biology Front. Cell Dev. Biol. 2020 8 594203 10.3389/fcell.2020.594203 33262988
210. Zou Y. He W. Wang K. Han H. Xiao T. Chen X. Zhou B. Tan J. Xia K. Tang B. Identification of rare RTN3 variants in Alzheimer’s disease in Han Chinese Hum. Genet. 2018 137 141 150 10.1007/s00439-018-1868-1 29356939
211. Jung W.H. Liu C.C. Yu Y.L. Chang Y.C. Lien W.Y. Chao H.C. Huang S.Y. Kuo C.H. Ho H.C. Chan C.C. Lipophagy prevents activity-dependent neurodegeneration due to dihydroceramide accumulation in vivo EMBO Rep. 2017 18 1150 1165 10.15252/embr.201643480 28507162
212. Heo J.M. Ordureau A. Paulo J.A. Rinehart J. Harper J.W. The PINK1-PARKIN Mitochondrial Ubiquitylation Pathway Drives a Program of OPTN/NDP52 Recruitment and TBK1 Activation to Promote Mitophagy Mol. Cell 2015 60 7 20 10.1016/j.molcel.2015.08.016 26365381
213. Lu K. Psakhye I. Jentsch S. Autophagic clearance of polyQ proteins mediated by ubiquitin-Atg8 adaptors of the conserved CUET protein family Cell 2014 158 549 563 10.1016/j.cell.2014.05.048 25042851
214. Lamark T. Johansen T. Aggrephagy: Selective disposal of protein aggregates by macroautophagy Int. J. Cell Biol. 2012 2012 736905 10.1155/2012/736905 22518139
215. Yang X. Zhang M. Dai Y. Sun Y. Aman Y. Xu Y. Yu P. Zheng Y. Yang J. Zhu X. Spermidine inhibits neurodegeneration and delays aging via the PINK1-PDR1-dependent mitophagy pathway in C. elegans Aging 2020 12 16852 16866 10.18632/aging.103578 32902411
216. Geisler S. Holmstrom K.M. Skujat D. Fiesel F.C. Rothfuss O.C. Kahle P.J. Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 Nat. Cell Biol. 2010 12 119 131 10.1038/ncb2012 20098416
217. Lahiri V. Klionsky D.J. Functional impairment in RHOT1/Miro1 degradation and mitophagy is a shared feature in familial and sporadic Parkinson disease Autophagy 2017 13 1259 1261 10.1080/15548627.2017.1327512 28598233
218. Chen Y. Dorn G.W. 2nd PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria Science 2013 340 471 475 10.1126/science.1231031 23620051
219. Gao F. Chen D. Si J. Hu Q. Qin Z. Fang M. Wang G. The mitochondrial protein BNIP3L is the substrate of PARK2 and mediates mitophagy in PINK1/PARK2 pathway Hum. Mol. Genet. 2015 24 2528 2538 10.1093/hmg/ddv017 25612572
220. Tang C. Han H. Liu Z. Liu Y. Yin L. Cai J. He L. Liu Y. Chen G. Zhang Z. Activation of BNIP3-mediated mitophagy protects against renal ischemia-reperfusion injury Cell Death Dis. 2019 10 677 10.1038/s41419-019-1899-0 31515472
221. Strappazzon F. Nazio F. Corrado M. Cianfanelli V. Romagnoli A. Fimia G.M. Campello S. Nardacci R. Piacentini M. Campanella M. AMBRA1 is able to induce mitophagy via LC3 binding, regardless of PARKIN and p62/SQSTM1 Cell Death Differ. 2015 22 419 432 10.1038/cdd.2014.139 25215947
222. Murakawa T. Yamaguchi O. Hashimoto A. Hikoso S. Takeda T. Oka T. Yasui H. Ueda H. Akazawa Y. Nakayama H. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation Nat. Commun. 2015 6 7527 10.1038/ncomms8527 26146385
223. Bhujabal Z. Birgisdottir A.B. Sjottem E. Brenne H.B. Overvatn A. Habisov S. Kirkin V. Lamark T. Johansen T. FKBP8 recruits LC3A to mediate Parkin-independent mitophagy EMBO Rep. 2017 18 947 961 10.15252/embr.201643147 28381481
224. Park S. Choi S.G. Yoo S.M. Son J.H. Jung Y.K. Choline dehydrogenase interacts with SQSTM1/p62 to recruit LC3 and stimulate mitophagy Autophagy 2014 10 1906 1920 10.4161/auto.32177 25483962
225. Wang Z.T. Lu M.H. Zhang Y. Ji W.L. Lei L. Wang W. Fang L.P. Wang L.W. Yu F. Wang J. Disrupted-in-schizophrenia-1 protects synaptic plasticity in a transgenic mouse model of Alzheimer’s disease as a mitophagy receptor Aging Cell 2019 18 e12860 10.1111/acel.12860 30488644
226. Wei Y. Chiang W.C. Sumpter R. Jr. Mishra P. Levine B. Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor Cell 2017 168 224 238 e210 10.1016/j.cell.2016.11.042 28017329
227. Chu C.T. Ji J. Dagda R.K. Jiang J.F. Tyurina Y.Y. Kapralov A.A. Tyurin V.A. Yanamala N. Shrivastava I.H. Mohammadyani D. Cardiolipin externalization to the outer mitochondrial membrane acts as an elimination signal for mitophagy in neuronal cells Nat. Cell Biol. 2013 15 1197 1205 10.1038/ncb2837 24036476
228. Princely Abudu Y. Pankiv S. Mathai B.J. Hakon Lystad A. Bindesboll C. Brenne H.B. Yoke Wui Ng M. Thiede B. Yamamoto A. Mutugi Nthiga T. NIPSNAP1 and NIPSNAP2 Act as “Eat Me” Signals for Mitophagy Dev. Cell 2019 49 509 525 e512 10.1016/j.devcel.2019.03.013 30982665
229. Lazarou M. Sliter D.A. Kane L.A. Sarraf S.A. Wang C. Burman J.L. Sideris D.P. Fogel A.I. Youle R.J. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy Nature 2015 524 309 314 10.1038/nature14893 26266977
230. Cao L.L. Guan P.P. Zhang S.Q. Yang Y. Huang X.S. Wang P. Downregulating expression of OPTN elevates neuroinflammation via AIM2 inflammasome- and RIPK1-activating mechanisms in APP/PS1 transgenic mice J. Neuroinflamm. 2021 18 281 10.1186/s12974-021-02327-4
231. Cen X. Chen Y. Xu X. Wu R. He F. Zhao Q. Sun Q. Yi C. Wu J. Najafov A. Pharmacological targeting of MCL-1 promotes mitophagy and improves disease pathologies in an Alzheimer’s disease mouse model Nat. Commun. 2020 11 5731 10.1038/s41467-020-19547-6 33184293
232. Yamada T. Dawson T.M. Yanagawa T. Iijima M. Sesaki H. SQSTM1/p62 promotes mitochondrial ubiquitination independently of PINK1 and PRKN/parkin in mitophagy Autophagy 2019 15 2012 2018 10.1080/15548627.2019.1643185 31339428
233. Cinque L. De Leonibus C. Iavazzo M. Krahmer N. Intartaglia D. Salierno F.G. De Cegli R. Di Malta C. Svelto M. Lanzara C. MiT/TFE factors control ER-phagy via transcriptional regulation of FAM134B EMBO J. 2020 39 e105696 10.15252/embj.2020105696 32716134
234. Fumagalli F. Noack J. Bergmann T.J. Cebollero E. Pisoni G.B. Fasana E. Fregno I. Galli C. Loi M. Solda T. Translocon component Sec62 acts in endoplasmic reticulum turnover during stress recovery Nat. Cell Biol. 2016 18 1173 1184 10.1038/ncb3423 27749824
235. Smith M.D. Harley M.E. Kemp A.J. Wills J. Lee M. Arends M. von Kriegsheim A. Behrends C. Wilkinson S. CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis Dev. Cell 2018 44 217 232 e211 10.1016/j.devcel.2017.11.024 29290589
236. Chen Q. Teng J. Chen J. ATL3, a cargo receptor for reticulophagy Autophagy 2019 15 1465 1466 10.1080/15548627.2019.1609862 31032711
237. Zheng J. Chen X. Liu Q. Zhong G. Zhuang M. Ubiquitin ligase MARCH5 localizes to peroxisomes to regulate pexophagy J. Cell Biol. 2022 221 e202103156 10.1083/jcb.202103156 34747980
238. Mochida K. Oikawa Y. Kimura Y. Kirisako H. Hirano H. Ohsumi Y. Nakatogawa H. Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus Nature 2015 522 359 362 10.1038/nature14506 26040717
239. Wyant G.A. Abu-Remaileh M. Frenkel E.M. Laqtom N.N. Dharamdasani V. Lewis C.A. Chan S.H. Heinze I. Ori A. Sabatini D.M. NUFIP1 is a ribosome receptor for starvation-induced ribophagy Science 2018 360 751 758 10.1126/science.aar2663 29700228
240. Xu X. Sun Y. Cen X. Shan B. Zhao Q. Xie T. Wang Z. Hou T. Xue Y. Zhang M. Metformin activates chaperone-mediated autophagy and improves disease pathologies in an Alzheimer disease mouse model Protein Cell 2021 12 769 787 10.1007/s13238-021-00858-3 34291435

